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A B S T R A C T
Background
Child and adolescent overweight and obesity have increased globally, and are associated with significant short and long term health
consequences.
Objectives
To assess the effects of surgical interventions for treating obesity in childhood and adolescence.
Search methods
We searched the Cochrane Library, MEDLINE, PubMed, EMBASE as well as LILACS, ICTRP Search Portal and ClinicalTrials.gov (all
from database inception toMarch 2015). References of identified studies and systematic reviews were checked. No language restrictions
were applied.
Selection criteria
We selected randomised controlled trials (RCTs) of surgical interventions for treating obesity in children and adolescents (age < 18
years) with a minimum of six months follow-up. Interventions that specifically dealt with the treatment of eating disorders or type 2
diabetes, or included participants with a secondary or syndromic cause of obesity were excluded. Pregnant females were also excluded.
Data collection and analysis
Two review authors independently assessed risk of bias and extracted data. Where necessary authors were contacted for additional
information.
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Main results
We included one RCT (a total of 50 participants, 25 in both the intervention and comparator group). The intervention focused
on laparoscopic adjustable gastric banding surgery, which was compared to a control group receiving a multi component lifestyle
programme. The participating population consisted of Australian adolescents (a higher proportion of girls than boys) aged 14 to 18
years, with a mean age of 16.5 and 16.6 years in the gastric banding and lifestyle group, respectively which was conducted in a private
hospital, receiving funding from the gastric banding manufacturer. The study authors were unable to blind participants, personnel and
outcome assessors which may have resulted in a high risk of performance and detection bias. Attrition bias was noted as well. The
study authors reported a mean reduction in weight of 34.6 kg (95% confidence interval (CI) 30.2 to 39.0) at two years, representing a
change in body mass index (BMI) of 12.7 (95% CI 11.3 to 14.2) for the surgery intervention; and a mean reduction in weight of 3.0
kg (95% CI 2.1 to 8.1) representing a change in BMI of 1.3 (95% CI 0.4 to 2.9) for the lifestyle intervention. The differences between
groups were statistically significant for all weight measures at 24 months (P < 0.001). The overall quality of the evidence according
to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) was low. Adverse events were reported in
12/25 (48%) participants in the intervention group compared to 11/25 (44%) in the control group (low quality evidence). A total of
28% of the adolescents undergoing gastric banding required revisional surgery. No data were reported for all-cause mortality, behaviour
change, participants views of the intervention and socioeconomic effects. At two years, the gastric banding group performed better than
the lifestyle group in two of eight health-related quality of life concepts (very low quality evidence) as measured by the Child Health
Questionnaire (physical functioning score (94 versus 78, community norm 95) and change in health score (4.4 versus 3.6, community
norm 3.5)).
Authors’ conclusions
Laparoscopic gastric banding led to greater body weight loss compared to a multi component lifestyle program in one small study with
50 patients. These results do not provide enough data to assess efficacy across populations from different countries, socioeconomic and
ethnic backgrounds, who may respond differently. This systematic review highlights the lack of RCTs in this field. Future studies should
assess the impact of the surgical procedure and post operative care to minimise adverse events, including the need for post operative
adjustments and revisional surgery. Long-term follow-up is also critical to comprehensively assess the impact of surgery as participants
enter adulthood.
P L A I N L A N G U A G E S U M M A R Y
Surgery for the treatment of obesity in children and adolescents
Review question
How effective is bariatric surgery in safely reducing weight in obese children and adolescents?
Background
Across the world more children and adolescents are becoming overweight and obese. As overweight and obese children are more likely
to suffer from health problems, more information is needed about how best to treat this problem.
Study characteristics
We found one randomised controlled trial with a total of 50 participants (25 in both the intervention and comparator group) and a
follow-up of two years. The surgery used was ’laparoscopic adjustable gastric banding’ (gastric band placed around the entrance of the
stomach by means of keyhole surgery). The control group received a program consisting of reduced energy intake (individualised diet
plans ranging between 800 and 2000 kcal per day, depending on age and weight), increased activity (target of 10,000 steps per day)
with a structured exercise schedule of at least 30 minutes a day and behavioural modification.
Key results
Australian adolescents (higher proportion of girls than boys) with an average age of 16.5 and 16.6 years in the gastric banding and
’lifestyle’ group participated. The study authors reported an average reduction in weight of 34.6 kg at two years, representing a change
in body mass index units (kg/m²) of 12.7 for the gastric banding group; and an average reduction in weight of 3.0 kg representing
a change in body mass index units of 1.3 for the lifestyle intervention. Side effects were reported in 12 of 25 (48%) participants in
the intervention group and in 11 of 25 (44%) in the control group. A total of 28% of the adolescents undergoing gastric banding
2Surgery for the treatment of obesity in children and adolescents (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
required a ’revisional procedure’ (surgery because of complications from the gastric banding surgery). No data were reported for all-
cause mortality, behaviour change, participants views of the intervention and socioeconomic effects. At two years, the gastric banding
participants performed better than the lifestyle participants in two of eight health-related quality of life concepts as measured by the
Child Health Questionnaire (physical functioning score (94 versus 78, community norm 95) and change in health score (4.4 versus
3.6, community norm 3.5).
Quality of the evidence
Our results are limited to two years of follow-up and are based on just one small Australian study with some risk of bias which was
conducted in a private hospital, receiving funding from the gastric banding manufacturer. There is currently insufficient evidence to
make an informed judgement about surgery for the treatment of obesity in children and adolescents.
Currentness of evidence
This evidence is up to date as of March 2015.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Surgery compared with a multi component lifestyle programme for obese children and adolescents
Population: children and adolescents with obesity
Settings: community, clinic
Intervention: laparoscopic adjustable gastric banding surgery
Comparison: multi component lifestyle programme
Outcomes Laparoscopic adjustable
gastric banding surgery
Multi component lifestyle
programme
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
a) BMI [kg/m²]
b) Weight loss [kg]
Follow-up: two years
a) -12.7 (-11.3 to -14.2)
b) -34.6 (-30.2 to -39.0)
a) -1.3 (-0.4 to -2.9)
b) -3.0 (-2.1 to -8.1)
50 (1) ⊕⊕©©
lowa
-
Adverse events [revisional
procedure]
Follow-up: two years
7/25 (28%) participants 0/25 (0%) 50 (1) ⊕⊕©©
lowb
-
Health-related quality of life
[CHQ (8 subscores); scale 0
to 100, where 0 indicates the
worst possible health state
and 100 the best possible
health state]c
a) physical functioning (com-
munity norm 95)
b) change in health (commu-
nity norm 3.5)
Follow-up: two years
a) 94
b) 4.4
a) 78
b) 3.6
50 (1) ⊕©©©
very lowd
-
All-cause mortality See comments See comments See comments See comments Not reported
Morbidity [metabolic syn-
drome]e
Follow-up: two years
0/24 (0%) participants com-
pleting the study
4/18 (22%) participants com-
pleting the study
50 (1) ⊕©©©
very lowf
-
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Socioeconomic effects See comments See comments See comments See comments Not reported
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
BMI: body mass index; CHQ: child health questionnaire; CI: confidence interval; RR: risk ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
aDowngraded by two levels because of one study only with small number of participants, and unclear risk of performance and detection
bias
bDowngraded by two levels because of one study only with small number of participants
cPoor health-related quality of life is defined as two standard deviations below the mean of the normative sample or a physical functioning
or psychosocial health summary score less than 30
dDowngraded by three levels because of one study only with small number of participants, and high risk of performance, detection and
attrition bias
eThe metabolic syndrome is a weak surrogate endpoint for illness or harm associated with the intervention or the condition
fDowngraded by three levels because of one study only with small number of participants, indirectness, and high risk of performance,
detection and attrition bias
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B A C K G R O U N D
The prevalence of overweight and obese children and adolescents
has increased throughout the world, presenting a global public
health crisis (Ng 2014; WHO 2015a). Although once considered
to be a condition affecting only developed countries, rates of pae-
diatric overweight and obesity have recently started to rise dra-
matically in some developing countries (Wang 2012). Using the
International Obesity Task Force (IOTF) standard definition the
age standardised prevalence of overweight and obesity in children
and adolescents has increased in both developed and developing
countries over the last thirty years (Cole 2000). In 2013 the preva-
lence of overweight and obese children and adolescents in devel-
oped countries was estimated at 23.8% (95% confidence interval
(CI) 22.9 to 24.7)) for boys and 22.6% (95% CI 21.7 to 23.6)
for girls. In developing countries the prevalence was estimated as
12.9% (95% CI 12.3 to 13.5) of boys and 13.4% (95% CI 13
to 13.9) of girls(Ng 2014). Very young children are also affected.
In 2010 De Onis 2010 used the WHO growth standards (WHO
2015b) to estimate that over 42 million children under five years
were overweight or obese, with approximately 35 million of these
children living in developing countries.
Inequalities in overweight and obesity prevalence have also been
documented. Generally, socioeconomically disadvantaged chil-
dren in developed countries (Knai 2012; Shrewsbury 2008), and
children of higher socioeconomic status in developing countries
(Lobstein 2004; Wang 2012), are at greater risk of becoming over-
weight. However, this relationship may vary by population de-
mographics (e.g. age, gender, ethnicity), and environment (e.g.
country, urbanisation) (Wang 2012). The prevalence of obesity
has been shown to vary by ethnicity, with large data sets showing
substantial ethnic variation in English (HSCIC 2015), American
(Freedman 2006; Skinner 2014), andNewZealand (Rajput 2014)
child populations.
Whilst there is some evidence that the rate of increase in paedi-
atric obesity may be slowing in some developed countries, cur-
rent levels remain too high, and continue to rise in many devel-
oping countries (Olds 2011; Rokholm 2010). However, an addi-
tional concern in some developed countries such as theUSA (Kelly
2013; Skinner 2014), and England (CMO 2015; Ells 2015), is
the rise in severe paediatric obesity. Whilst the IOTF published
an international definition for severe paediatric (morbid) obesity
in 2012 (Cole 2012), often severe obesity prevalence is reported
using country specific cut points making international compar-
isons difficult. However, data from the USA (Skinner 2014) and
England (Ells 2015) has shown that the prevalence of severe pae-
diatric obesity varies by socioeconomic status and ethnicity, and
may result in a greater risk of adverse cardio-metabolic events and
severe obesity in adulthood (Kelly 2013).
Description of the condition
Childhood overweight and obesity results from an accumulation
of excess body fat, and can increase the risk of both short and
longer term health consequences. Numerous obesity related co-
morbidities can develop during childhood, which include mus-
cular skeletal complaints (Paulis 2014); cardiovascular risk fac-
tors such as hypertension, insulin resistance and hyperlipidaemia
(Reilly 2003), even in very young children (Bocca 2013); and
conditions such as such as sleep apnoea (Narang 2012), asthma
(Egan 2013), liver disease, and type 2 diabetes (Daniels 2009;
Lobstein 2004). The condition can also affect psychosocial well
being, with obese young people susceptible to reduced self esteem
and quality of life (Griffiths 2010), and stigmatisation (Puhl 2007;
Tang-Peronard 2008). Evidence also shows that childhood obesity
can track into adulthood (Parsons 1999; Singh 2008; Whitaker
1997), and is therefore associatedwith an increased risk of ill health
in later in life (Reilly 2011).
Description of the intervention
Given the serious implications associated with childhood and ado-
lescent obesity, effective treatment is imperative. Whilst the fun-
damental principles of weight management in children and ado-
lescents are the same as adults (i.e. reduced energy intake and in-
creased energy expenditure), the primary aim of treatment (i.e.
weight reduction or deceleration of weight gain) and themost suit-
able intervention approach varies, and is dependent on the child’s
age and degree of excess weight, among other considerations.
Bariatric surgery is an established treatment for severely obese
adults (Colquitt 2014), however the role of surgery in severely
obese children and adolescents is less clear. In some severely obese
adolescents both adolescents and clinicians may consider surgery
to be a pragmatic last solution to reduce body mass index (BMI)
and associated comorbidities, and improve health-related quality
of life.
Adverse effects of the intervention
Bariatric surgery is a major surgical intervention, with risk of seri-
ous operative and perioperative complications and mortality. De-
pending on the type of surgery, adverse effects can include nutrient
deficiencies, hernia, cholelithiasis, wound infections, pouch dila-
tion, ulcers, port leakage and slippage (Black 2013). The restric-
tive or malabsorptive nature of some forms of bariatric surgery is
an additional consideration in growing children, with guidelines
largely agreeing that eligible candidates must be severely obese
adolescents that have reached or nearly reached physical maturity
(Baur 2011; Brei 2013). Additional considerations in adolescents
include developmental issues around ability to consent and the
need for family support. This is particularly important given se-
vere obesity can be a comorbidity in some children with learning
disabilities, with potentially limited ability to both consent and
adhere to dietary regimes required for safe surgery. Contraindica-
6Surgery for the treatment of obesity in children and adolescents (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
tions to surgery include capacity to consent, pregnancy or breast
feeding, medically correctable causes of obesity, substance abuse
and a disability that may prevent adherence to post operative man-
agement (Hsia 2012).
How the intervention might work
Bariatric surgery aims to work by restricting intake, and by reduc-
ing the absorption of food. A number of different surgical pro-
cedures exist. The most common procedures include: Roux-en-
Y gastric bypass which is a procedure combining restriction and
malabsorption, adjustable banding and sleeve gastrectomy which
are restrictive procedures, and biliopancreatic diversion which is a
mostly malabsorptive procedure (Colquitt 2014; Hsia 2012). The
most commonly performed procedures in adolescents are: the la-
paroscopic Roux-en-Y gastric bypass, which involves the surgical
alteration of the gastrointestinal anatomy to create a small stomach
pouch, which is joined directly to the middle section of small in-
testine, thus restricting food intake and reducing food absorption
by passing the upper section of the small intestine, and the laparo-
scopic adjustable gastric band, which is the least invasive restrictive
procedure involving the placement of an adjustable band around
the upper section of stomach, to create a small gastric pouch that
restricts food intake (Aikenhead 2011). There is also an increasing
number of laparoscopic sleeve gastrectomies (the surgical reduc-
tion of stomach size) being performed. However, bypass is recog-
nised the ’gold standard’ procedure with relatively low quality ob-
servational data suggesting it is associated with greater weight loss
than the gastric sleeve or band (Black 2013).
Why it is important to do this review
The first version of this systematic review was published in 2003
(Summerbell 2003), and included analysis of childhood obesity
treatment studies publishedupuntil July 2001.The second version
was published in 2009 providing an update to the 2003 review
(Oude Luttikhuis 2009).
To reflect the rapid growth in this field, the third update to this
review has been split across six reviews focusing on the following
treatment approaches: surgery; drugs; parent only interventions;
diet, physical activity and behavioural interventions for young
children aged 0 to 4 years; school children aged 5 to 11 years; and
adolescents aged 12 to 17 years. This is the first review in this series
which focuses on the efficacy of surgical interventions for obese
children and adolescents. The review complements the Cochrane
review on surgery for obesity (Colquitt 2014), and a Health Tech-
nology Assessment review (Picot 2009), which do not provide
randomised controlled trial (RCT) data on bariatric surgery for
children and adolescents. It is also important to note that future
updates of the Colquitt 2014 review will exclude studies involving
children and adolescents. The results of this current review and
other systematic reviews in this series will provide information to
inform clinical guidelines and health policy for the treatment of
childhood obesity.
O B J E C T I V E S
To assess the effects of surgery for treating obesity in children and
adolescents.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs).
Types of participants
We included study groups consisting of obese participants, with
a mean age of less than 18 years at the commencement of the
intervention. Pregnant females and the critically ill were excluded,
as were children with obesity due to a secondary or syndromic
cause (e.g. Prader-Willi syndrome).
Types of interventions
We investigated the following comparisons of intervention versus
control or comparator where the same letters indicate direct com-
parisons.
Intervention
(a) Surgery.
(b) Surgery + other therapy.
Comparator
• Placebo compared with (a).
• Usual care (non surgical treatment) compared with (a).
• Placebo + other therapy compared with (b).
• Usual care (non surgical treatment) + other therapy
compared with (b).
Concomitant therapieswere the same in the intervention and com-
parator groups.
Types of outcome measures
Primary outcomes
• BMI and weight loss.
• Adverse events.
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Secondary outcomes
• Health-related quality of life and self esteem.
• All-cause mortality.
• Morbidity (changes in disease status).
• Measures of body fat distribution.
• Behaviour change.
• Participants views of the intervention.
• Socioeconomic effects.
Method and timing of outcome measurement
• BMI: defined as weight (kg) divided by height (m) squared
and weight loss defined as loss in weight in kg from baseline,
measured at baseline, 6, 12 and 24 months.
• Adverse events: defined as an adverse outcome that occurs
during or after the intervention but is not necessarily caused by
it, and measured at baseline, 6, 12 and 24 months.
• Health-related quality of life and self esteem: evaluated by a
validated instrument such as Paediatric Quality of Life Inventory
and measured at baseline, 6, 12 and 24 months.
• All-cause mortality: defined as any death that occurred
during or after the intervention and measured at baseline, 6, 12
and 24 months.
• Morbidity: defined as illness or harm associated with the
intervention or the condition and measured at baseline, 6, 12
and 24 months.
• Measures of body fat distribution: defined by the use of
validated tools such as DXA, waist circumference, skin fold
thickness, waist to hip ratio, dual x-ray absorptiometry or
bioelectrical impedance analysis and measured at baseline, 6, 12
and 24 months.
• Behaviour change: defined as validated measures of diet or
physical activity (Bryant 2014), and measured at baseline, 6, 12
and 24 months.
• Participants views of the intervention: defined as
documented accounts from participant feedback and measured
at baseline, 6, 12 and 24 months.
• Socioeconomic effects: defined as a validated measure of
socioeconomic status such as parental income or educational
status and measured at baseline, 6, 12 and 24 months.
’Summary of findings’ table
We present a ’Summary of findings table’ reporting the following
outcomes listed according to priority.
1. BMI and weight loss.
2. Adverse events.
3. Health-related quality of life.
4. All-cause mortality.
5. Morbidity.
6. Socioeconomic effects.
Search methods for identification of studies
Electronic searches
We searched the following sources on the 30th ofMarch 2015 from
inception to the specified database date and placed no restrictions
on the language of publication.
• Cochrane Library:
◦ Cochrane Database of Systematic Reviews (until issue
3, 2015).
◦ Database of Reviews of Effects (until issue 1, 2015).
◦ Cochrane Central Register of Controlled Trials (until
issue 2, 2015).
◦ Health Technology Assessment Database (until issue
1, 2015).
• MEDLINE (until 30th March 2015).
• EMBASE (until week 13, 2015).
• PubMed (only subsets not available on Ovid) (until 30th
March 2015).
• LILACS (until 25th February 2015).
• ClinicalTrials.gov (until 30th March 2015).
• World Health Organization (WHO) International Clinical
Trials Registry Platform (ICTRP) - http://apps.who.int/
trialsearch/, a meta-register of studies with links to several trial
registers, including:
◦ Australian New Zealand Clinical Trials Registry (23th
March 2015).
◦ Chinese Clinical Trial Registry (23th March 2015).
◦ ClinicalTrials.gov (23th March 2015).
◦ EU Clinical Trials Register (EU-CTR) (23th March
2015).
◦ ISRCTN (23th March 2015).
◦ The Netherlands National Trial Register (23th March
2015).
◦ Brazilian Clinical Trials Registry (ReBec) (16th March
2015).
◦ Clinical Trials Registry - India (2nd March 2015).
◦ Clinical Research Information Service - Republic of
Korea (3rd March 2015).
◦ Cuban Public Registry of Clinical Trials (3rd March
2015).
◦ German Clinical Trials Register (3rd March 2015).
◦ Iranian Registry of Clinical Trials (3rd March 2015).
◦ Japan Primary Registries Network (3rd March 2015).
◦ Pan African Clinical Trial Registry (9th March 2015).
◦ Sri Lanka Clinical Trials Registry (2nd March 2015).
◦ Thai Clinical Trials Register (TCTR) (3rd March
2015).
For detailed search strategies see Appendix 1. This strategy was
based on the search undertaken byOude Luttikhuis 2009, but was
8Surgery for the treatment of obesity in children and adolescents (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
revised and adapted to expand the surgery search terms to cap-
ture the numerous different surgical interventions and associated
nomenclature. We continuously applied a MEDLINE (via Ovid)
email alert service to identify newly published studies using the
search strategy detailed in Appendix 1. After supplying the final
review draft for editorial approval, the Cochrane Metabolic and
Endocrine Disorders (CMED) Group performed a complete up-
date search on all databases available at the editorial office and sent
the results to the review authors. In case we identified new studies
for inclusionwewould have evaluated these, incorporated findings
in our review and resubmitted another review draft (Beller 2013).
Searching other resources
We tried to identify other potentially eligible trials or ancillary
publications by searching the reference lists of retrieved included
trials, (systematic) reviews, meta-analyses and health technology
assessment reports.
Data collection and analysis
Selection of studies
To determine the studies to be assessed further, two review authors
(LJE, EM) independently scanned the abstract, title, or both, of
every record retrieved by the searches. We investigated all poten-
tially relevant articles as full text. Where differences in opinion
existed, they were resolved by discussion and consensus with a
third review author (GA). If resolving disagreement was not pos-
sible, the article was added to those ’Studies awaiting classifica-
tion’ and we contacted study authors for clarification. We present
an adapted Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) flow diagram reporting the process of
study selection (Liberati 2009).
Data extraction and management
For studies that fulfilled inclusion criteria, two review authors
(LJE, KR, or EM) independently extracted key participant and in-
tervention characteristics and reported data on efficacy outcomes
and adverse events using a standard data extraction form supplied
by the CMED Group. Disagreements were to be resolved by dis-
cussion, or if required by a third review author (GA) (for details see
Characteristics of included studies; Table 1; Appendix 2; Appendix
3; Appendix 4; Appendix 5; Appendix 6; Appendix 7; Appendix
8; Appendix 9; Appendix 10).
We provide information about potentially-relevant ongoing stud-
ies including trial identifier in the Characteristics of ongoing
studies table and in Appendix 5 ’Matrix of study endpoints (pub-
lications and trial documents)’. We tried to find the protocol for
each included study, either in databases of ongoing trials, in pub-
lications of study designs, or both. We sent an email request to
the author of the included study to enquire whether further un-
published data relating to the study were available, whether the
trial was ongoing and whether they were involved with any new
studies in this area (Appendix 11).
Dealing with duplicate publications and companion papers
In the event of duplicate publications and companion papers of
a primary study, we tried to maximise yield of information by
simultaneous evaluation of all available data. In case of doubt, we
will give priority to the publication reporting the longest follow-
up associated with our primary or secondary outcomes.
Assessment of risk of bias in included studies
Two review authors (LJE, KR) independently assessed the risk of
bias of each included study. Possible disagreements were resolved
by consensus, or by consultation with a third review author (EM).
In cases of disagreement, the rest of the group was consulted and
a judgement was made based on consensus.
We planned to assess risk of bias using the Cochrane risk of bias
tool (Higgins 2011a; Higgins 2011b). We applied the following
criteria.
• Random sequence generation (selection bias).
• Allocation concealment (selection bias).
• Imbalances in baseline characteristics (chance bias).
• Blinding (performance bias and detection bias), separated
for blinding of participants and personnel and blinding of
outcome assessment.
• Incomplete outcome data (attrition bias).
• Selective reporting (reporting bias).
• Other bias.
We evaluated whether imbalances in baseline characteristics ex-
isted and how these were addressed (Egbewale 2014; Riley 2013).
We assessed outcome reporting bias by integrating the results of
’Examination of outcome reporting bias’ (Appendix 6), ’Matrix
of study endpoints (publication and trial documents)’ (Appendix
5) and ’Outcomes (outcomes reported in abstract of publication)’
of the ’Characteristics of included studies’ table (Kirkham 2010).
This analysis formed the basis for the judgement of selective re-
porting (reporting bias) (Boutron 2014; Mathieu 2009).
We judged risk of bias criteria as ’low risk’, ’high risk’ or ’un-
clear risk’ and evaluated individual bias items as described in the
CochraneHandbook for Systematic Reviews of Interventions (Higgins
2011a). We report a ’Risk of bias summary’ in the results.
We assessed the impact of individual bias domains on study results
at endpoint and study levels.
For blinding of participants and personnel (performance bias),
detection bias (blinding of outcome assessors) and attrition bias
(incomplete outcome data) we evaluated risk of bias separately
for each outcome (Hróbjartsson 2013). We noted whether end-
points were self-reported or investigator-assessed. We considered
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the implications of missing outcome data from individual partici-
pants per outcome such as high drop-out rates (e.g. above 15%) or
disparate attrition rates (e.g. difference of 10% or more between
study arms).
We defined the following outcomes as self-reported outcomes.
• BMI and weight loss, if measured by participants.
• Adverse events, if reported by participants.
• Health-related quality of life and self esteem.
• Participants views of the intervention.
• Behaviour change.
We defined the following outcomes as investigator-assessed out-
comes.
• BMI, weight loss and measures of body fat distribution, if
measured by study personnel.
• Adverse events, if reported by study personnel.
• All-cause mortality.
• Morbidity (changes in disease status).
• Socioeconomic effects.
Measures of treatment effect
For dichotomous outcomes we calculated odds ratio (OR) or risk
ratio (RR) and corresponding 95% confidence interval (CI). For
continuous outcomes we calculated the mean difference (MD)
and corresponding 95% CI.
Unit of analysis issues
We planned to take into account the level at which randomisation
occurred, such as cross-over trials, cluster-randomised trials and
multiple observations for the same outcome.
Dealing with missing data
If feasible, we obtained relevant missing data from authors. We
evaluated important numerical data such as screened, eligible, and
randomised patients as well as intention-to-treat (ITT), as-treated
and per-protocol (PP) populations. We investigated attrition rates
(e.g. drop-outs, losses to follow-up, withdrawals), and we critically
appraised issues concerning missing data and imputation methods
(e.g. last observation carried forward (LOCF)).
If standard deviations for outcomes were not reported, we would
have imputed these values by assuming the standard deviation of
the missing outcome to be the average of the standard deviations
from those studies where this information was reported. If more
than one study were available, we would have investigated the
impact of this imputation on the point estimate using a sensitivity
analysis.
Assessment of heterogeneity
Ifmore than one paper had been identified and substantial clinical,
methodological or statistical heterogeneity had been identified, we
would not have reported study results as meta-analytically pooled
effect estimates. Heterogeneity would have been identified by vi-
sual inspection of the forest plots and by using a standard Chi²
test with a significance level of α = 0.1, in view of the low power
of this test. If more than one study had been identified we would
have examined heterogeneity using the I² statistic, which quan-
tifies inconsistency across studies to assess the impact of hetero-
geneity on themeta-analysis (Higgins 2002; Higgins 2003); where
an I² statistic of 75% or more indicates a considerable level of
inconsistency (Higgins 2011a). If heterogeneity had been found,
we would have attempted to determine potential reasons for it by
examining individual study and subgroup characteristics.
We expected the following characteristics to introduce clinical het-
erogeneity.
• Differences in the age of study population.
• Differences in the study population demographics.
• Differences in the types of surgery preformed.
• Differences in BMI at baseline.
Assessment of reporting biases
If we included 10 studies or more for a given outcome, we planned
to use funnel plots to assess small study effects. Due to several
potential explanations for funnel plot asymmetry we planned to
interpret results carefully (Sterne 2011).
Data synthesis
Unless there was good evidence for homogeneous effects across
studies we planned to primarily summarise low-risk of bias data
by means of a random-effects model (Wood 2008).We planned to
interpreted random-effects meta-analyses with due consideration
of the whole distribution of effects, ideally by presenting a pre-
diction interval (Higgins 2009). A prediction interval specifies a
predicted range for the true treatment effect in an individual study
(Riley 2011). In addition, if statistical analyses were possible these
would have been performed according to the statistical guidelines
provided by the Cochrane Handbook for Systematic Reviews of In-
terventions (Higgins 2011a).
Subgroup analysis and investigation of heterogeneity
We planned to carry out the following subgroup analyses and
wanted to investigate interaction.
• Length of follow-up.
• Impact and nature of maintenance periods.
• The impact of comparator or control: whether concomitant
therapy or no treatment (true control).
• The impact of population demographics.
Sensitivity analysis
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We planned to perform sensitivity analyses in order to explore the
influence of the following factors (when applicable) on effect size
by restricting the analysis to:
• Published studies.
• Taking into account risk of bias, as specified in the
Assessment of risk of bias in included studies section.
• Very long or large studies to establish how much these
studies dominate the results.
• Studies using the following filters: diagnostic criteria,
language of publication, source of funding (industry versus
other), country.
We also tested the robustness of the results by repeating the analysis
using different measures of effect size (RR, OR etc) and different
statistical models (fixed-effect and random-effects models).
R E S U L T S
Description of studies
For a detailed description of studies, see Characteristics of included
studies, Characteristics of excluded studies, and Characteristics of
ongoing studies.
Results of the search
The initial search on30March 2015 identified 2405 records (2290
from database searches and 115 from trial registry searches); from
these, 11 full text publications and protocols were identified for
further examination and four trials met the inclusion criteria for
ongoing studies. We excluded the other studies because they did
not meet the inclusion criteria or were not relevant to the question
under study (see Figure 1 for the amended PRISMA (preferred
reporting items for systematic reviews and meta-analyses) flow di-
agram). After screening the full text of the selected publications,
one study (one publication) met the inclusion criteria. All studies
were published in English. We contacted the author of the pub-
lished study and received a reply to confirm that no further data
were available.
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Figure 1. Study flow diagram.
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Included studies
A detailed description of the characteristics of included studies is
presented elsewhere (see Characteristics of included studies and
appendices). The following is a succinct overview:
Source of data
One published study was included in this review (O’Brien 2010).
Four additional studies were identified from trial registry searches
(ACTRN12609001004257; NCT01172899; NCT01700738;
NCT02378259), but these could not be included as outcome data
were not yet available. Details of these studies are provided in the
Characteristics of ongoing studies table.
Comparisons
O’Brien 2010 compared laparoscopic adjustable gastric banding
surgery to amulti component lifestylemodification program, con-
sisting of individual calorie reduction diet plans, increased physical
activity through pedometer targets, structured exercise schedules,
advice to reduce sedentary activity and support through consulta-
tion with a health care practitioner every six weeks.
Overview of study populations
A total of 50 participants were included in the trial, 25 partici-
pants were randomised to intervention and 25 to control groups.
Twenty-four (98%) participants finished the study in the interven-
tion compared to 18 (72%) participants in the control group.
Study design
The included study was a randomised parallel group superiority
trial. Given the nature of the intervention under investigation it
was not possible to blind toparticipants or personnel delivering the
interventions. However, outcome assessors were also unblinded.
The duration of the intervention was two years, conducted be-
tween August 2006 and September 2008. The study was not ter-
minated early.
Settings
The studywas undertaken in a specialist weightmanagement clinic
either in the community or the Royal Children’s Hospital, Mel-
bourne, with surgery occurring at a private hospital.
Participants
The participating population consisted of Australian adolescents
aged 14 to 18 years, with a mean age of 16.5 and 16.6 years in the
banding and lifestyle group respectively. All participants demon-
strated substantial physiological maturity with secondary sexual
characteristics and most had also completed bone growth. This
study contained a higher proportion of girls than boys in each arm
of the intervention: 36% of the banding group were males and
28% of the lifestyle group were males. No further demographic
information was reported. The mean body mass index (BMI) at
baseline was 42.3 (SD 6.1) kg/m² in the banding group compared
to 40.4 (SD 3.1) kg/m² in the lifestyle group. Entry criteria are
outlined in the Characteristics of included studies table. Major ex-
clusion criteria were intellectual disability and syndromic obesity.
Diagnosis
Participants in the O’Brien 2010 study were required to have a
BMI greater than 35 and identifiable medical complications such
as metabolic syndrome, physical limitation such as an inability to
play a sport, or psycho-social difficulties such as low self-esteem.
Interventions
This study employed a two month run-in program, which all
participants undertook prior to randomisation. The program in-
volved the implementation of best practice guidance on healthy
eating and physical activity. The surgical intervention consisted of
the gastric band placement followed by detailed guidance on post
operative eating and activity.
Outcomes
The one included study assessed 50 participants, and reported data
for all primary and some secondary endpoints. All cause mortality,
behaviour change, participants views of the intervention, socioe-
conomic effects and costs were not reported in this study. For a
summary of all outcomes assessed in each study, see Appendix 5.
Excluded studies
Six studies had to be excluded after careful evaluation of the full
publication (Aikenhead 2011; Black 2013; Farina 2012; Gloy
2013; Picot 2009; Tyvonchuk 2009; see Figure 1).
Risk of bias in included studies
For details on risk of bias of included studies see Characteristics
of included studies. For an overview of review authors’ judgments
about each risk of bias item for the one included study see Figure 2.
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We investigated performance bias, detection bias and attrition bias
separately for objective and subjective outcome measures. ’Objec-
tive outcome’ measures were defined as all measured outcome data
(for the O’Brien 2010 study this included height, weight and all
health outcome data). ’Subjective outcome’ measures were defined
as all self reported outcome data (for the O’Brien 2010 study this
included self reported health-related quality of life data).
Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study (blank cells indicate that the study did not measure that particular outcome).
Allocation
The included study was judged to have an unclear risk of bias
for randomisation given a mismatch in information between the
study publication and data in the trial register.
Imbalances in baseline characteristics (chance bias)
There were no substantial differences in baseline characteristics
between the intervention and comparator group.
Blinding
O’Brien 2010 explicitly stated that the study was not blinded.
However, blinding of the participants and personnel delivering the
intervention was not possible given the nature of this study.Whilst
the impact of no blinding on performance bias was judged to be
unclear for objectively measured outcomes, it was felt that it posed
a potentially high risk for the subjectively reported health-related
quality of life measures. The impact of no blinding on detection
bias was judged to be high risk for the subjective (health-related
quality of life) and unclear for the objective measures as outcome
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assessors were not blinded.
Incomplete outcome data
O’Brien 2010 reported on withdrawals and losses to follow-up,
with one loss to follow-up in the banding intervention and two
losses to follow-up and five withdrawals in the lifestyle interven-
tion (due to family problems, unsatisfied with progress). Inten-
tion-to-treat (ITT) analysis was performed for the primary out-
come (weight change) only, all secondary outcomes (health-related
quality of life outcomes) were assessed by completers analysis as
the study was only powered to detect changes in the primary out-
come measure. Consequently attrition bias was considered to be
low risk for objectively measured outcomes such as the primary
outcome weight loss. The primary outcome was analysed using
ITT and disparate attrition rates probably did not contribute sig-
nificantly to this outcome. Bias for subjective measures (health-
related quality of life) was considered high as, no ITT analysis was
conducted and disparate attrition rates probably influenced this
outcome measure.
Selective reporting
Comparison of the study publication and protocol information in
the trial register revealed some differences and reporting bias was
therefore judged to be ’unclear’.
Other potential sources of bias
The study received some funding from the gastric band manufac-
turer (Allergen) and one of the co-authors declared his position as
a member of the Allergen advisory board. However, the authors
state that the sponsors had no role in the study design, conduct,
data collection and analysis and manuscript preparation.
Effects of interventions
See: Summary of findings for the main comparison
Baseline characteristics
For details of baseline characteristics, see Appendix 3 andAppendix
4.
Gastric banding program versus lifestyle program
The included study examined the effects of laparoscopic gastric
banding surgery compared to a form of lifestyle program (O’Brien
2010). This study measured weight change as the primary out-
come.
Primary outcomes (body mass index (BMI), weight loss,
adverse events)
BMI, weight loss
The study authors reported a mean reduction in weight of 34.6 kg
(95% confidence interval (CI) 30.2 to 39.0) at two years, repre-
senting a change in BMI units of 12.7 (95% CI 11.3 to 14.2) for
the surgery intervention; and a mean reduction in weight of 3.0
kg (95% CI 2.1 to 8.1) representing a change in 1.3 BMI units
(95% CI 0.4 to 2.9) for the lifestyle intervention. The differences
between groups was statistically significant for all weight measures
at 24 months (P < 0.001). All analyses were based on an ITT
model.
Adverse events
The gastric banding placement occurred without any complica-
tions during the perioperative period or within 30 days. The mean
length of hospital stay was 26 hrs (range 23 hrs to 32 hrs). A total
of 28% of the participants required a revisional procedure. Al-
though we generally considered the risk of performance, detection
and attrition bias to be high for adverse events, the risk of these
biases was appraised as low for revisional procedures.
Adverse events were reported in both groups, with 13 events re-
ported in 12 participants in the surgery intervention compared to
18 events reported in 11 participants in the lifestyle group, Adverse
events in the surgery group included six proximal gastric enlarge-
ments, two needlestick injury to tubing, one cholecystectomy, one
hospital admission for depression, one lost to follow-up and two
unplanned pregnancies. Adverse events in the lifestyle group in-
cluded one hospital admission for depression and intracranial hy-
pertension, one cholecystectomy, seven loss to follow-up and two
unplanned pregnancies.
Over the two year study period the surgical group (n = 25) had a
mean of 20 visits with a physician (range 10 to 31) per participant
and a mean of 9.5 adjustments made to the volume of saline in the
band (range 5 to 18) per participant. In the non-surgical group (n
= 25) adolescents visited the adolescent physician, study dietitian,
study nurse practitioner, or other physicians a mean of 16 (range 7
to 31) times. There was also a mean of 5 telephone consultations
per participant and each participant had 6 sessions with a personal
trainer.
Secondary outcomes (health-related quality of life and self
esteem; all-cause mortality; morbidity; measures of body fat
distribution; behaviour change; participants views of the
intervention; socioeconomic effects)
All-cause mortality, behaviour change, self-esteem, participants
views of the intervention and socioeconomic effects were either
not investigated or reported in the included study.
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Health-related quality of life
Health-related quality of life was assessed by the Child Health
Questionnaire™ (CHQ), a family of generic quality of life instru-
ments that have been designed and validated for children 5 to 18
years of age. Parents and children (ages10 to 18 years) may self-ad-
minister the CHQ after instructions from the administrator. The
CHQ measures 14 unique physical and psychosocial concepts.
The parent form is available in two lengths - 50 or 28 items. Scores
can be analysed separately, the CHQ profile scores, or combined
to derive an overall physical and psychosocial score, the CHQ
summary scores.
Score interpretation: the range on subscales and the overall scale
is 0 to 100, where 0 indicates the worst possible health state and
100 the best possible health state. A normative sample was not
available for comparison of paediatric patient-reported health-re-
lated quality of life. Poor health-related quality of life has been de-
fined as two standard deviations below the mean of the normative
sample or a physical functioning or psychosocial health summary
score less than 30.
Eight of the subscores of the CHQ are shown in Appendix 12.
The subscores for behavioral, emotional, and physical limitations
are not shown because these items did not differ from community
values at entry into the study and were not different within or be-
tween groups over the two-year follow-up period. No statistically
significant differences existed in any measures between groups at
the commencement of the study. Both groups had six subscores
below the community norm at commencement. At two years, the
gastric banding group had better physical functioning scores (94
versus 78, community norm 95) and change in health scores (4.4
versus 3.6, community norm 3.5) than the lifestyle group.
Morbidity
Morbidity was associated with the metabolic syndrome which is a
weak surrogate endpoint for illness or harm associated with the in-
terventionor the condition itself. At study entry, 36%of the partic-
ipants in the gastric banding group and 40% in the lifestyle group
were diagnosed with themetabolic syndrome. At 24months, none
of the 24 study completers (0%) in the gastric banding group had
themetabolic syndrome compared to four of 18 completers (22%)
in the lifestyle group who still had the metabolic syndrome.
Measures of body fat distribution
Waist circumferencewas reducedby 28.2 cm in the gastric banding
group and by 3.5 cm in the lifestyle group at two years (MD) -
24.7 cm (95% CI -33.1 to -16.3); P < 0.001.
Ongoing studies
NCT01172899 and NCT01700738 both report the recruit-
ment of obese 12 to 16 year olds to assess the efficacy of gas-
tric banding in French (NCT01700738), and Dutch popula-
tions (NCT01172899), with completion anticipated in 2015.
ACTRN12609001004257 reports the recruitment of 44 of 50
planned obese 12 to 17 year olds to assess the efficacy of a Bioen-
terics Intragastric Balloon (BIB) in an Australian population. This
study started recruitment in 2009 but does not report an end date.
NCT02378259 is the most recently registered trial, and aims to
recruit 13 to 15 year olds to assess the efficacy of Roux-en-Y gastric
bypass in Sweden. This study is due to start in August 2015, with
completion anticipated for May 2021.
D I S C U S S I O N
Only five studies were identified that met the inclusion criteria
for this review: four ongoing studies (ACTRN12609001004257;
NCT01172899;NCT01700738;NCT02378259), and one pub-
lished study (O’Brien 2010). One ongoing study examined the
effect of Bioenterics Intragastric Balloon (BIB) insertion over
six months compared to a usual care 10 week multidisciplinary
lifestylemodification programme in an Australian adolescent pop-
ulation. Another Swedish ongoing study, due to start in Au-
gust 2015, aims to examine the impact of Roux-en-Y-gastric
bypass compared to intensive conservative treatment in 13 to
15 year old adolescents. Three studies investigate the impact
of laparoscopic gastric banding in obese adolescents from Aus-
tralia (O’Brien 2010), Netherlands (NCT01172899), and France
(NCT01700738), and measure change in weight status, associ-
ated morbidity, adverse events and health-related quality of life.
As only one study has reached completion and published findings
no further narrative or quantitative comparisons could be made.
O’Brien 2010 demonstrated that in a small, predominantly female
population of severely obese Australian adolescents both gastric
banding and a multi component lifestyle intervention resulted in
improved weight and health status. However, gastric banding re-
sulted in significantly greater weight loss than the lifestyle pro-
gram. Adverse events were reported in both arms of the study,
with two unplanned pregnancies and two hospital admissions for
depression and cholecystectomy occurring in both groups. An ad-
ditional eight (28%) admissions for revisional surgery occurred
in the banding group, which is a high rate and requires further
consideration.
Eating small meals slowly is central to avoiding problems after the
gastric banding procedure. This was repeatedly stressed during the
O’Brien 2010 study. For adolescents, additional education and
supervision of eatingmay help reduce the need for revision surgery.
Recruitment methods were used to minimise bias toward one or
other treatment butmay have drawn on a subset of the community
attracted by the availability of free treatment. The O’Brien 2010
study was powered to measure differences in weight outcomes
rather than differences in other health measures or adverse events.
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Adolescents and parents must understand the importance of care-
ful adherence to recommended eating behaviours and of seeking
early consultation if symptoms of reflux, heartburn, or vomiting
occur. As importantly, they should be in a setting in which they
can maintain contact with health professionals who understand
the process of care.
Summary of main results
This review reports the findings from one RCT (50 participants).
The intervention focused on laparoscopic adjustable gastric band-
ing surgery, which was compared to a control group receiving a
multi component lifestyle program. The study authors were un-
able to blind their participants, personnel and outcome assessors
which may have resulted in a high risk of performance and detec-
tion bias. At 24 months follow-up, the mean change in BMI units
was 12.7 (95% CI 11.3 to 14.2) in the surgery group compared to
1.3 (95% CI 0.4 to 2.9) in the control group. Adverse events were
reported in 12/25 participants in the intervention group compared
to 11/25 in the control group.
Overall completeness and applicability of
evidence
In line with the previous update (Oude Luttikhuis 2009), and the
other reviews in this series examining interventions for the treat-
ment of child and adolescent obesity, study design was limited
to randomised controlled trials (RCT) to provide the least biased
estimate of effect size (Stephenson 1998). Despite the publication
of a number of observational studies examining bariatric surgery
in young people under 18 years (Black 2013), only one RCT was
identified (O’Brien 2010). Whilst this study reported on weight,
health-related quality of life and adverse events, further data on
the participant socioeconomic status and ethnic origin may have
enhanced the wider applicability of the findings. The authors state
their uncertainty as to whether the study population is an accu-
rate reflection of the general obese adolescent population, since it
may have attracted a subset of the community amenable to the
availability of free treatment.
Quality of the evidence
Whilst the included study was well conducted and provides much
needed evidence in this field, further studies are required to
strengthen the evidence base. TheO’Brien 2010 study would have
benefited from outcome assessor blinding for the BMI and health-
related quality of life assessment and a cost effectiveness analysis.
It would also have been useful if O’Brien 2010 had reported the
exact baseline adjusted group difference in change scores.
Potential biases in the review process
As only one published study was comprehensively assessed in this
review, no potential biases in the review process arose.
Agreements and disagreements with other
studies or reviews
The findings from this review agree with the most recent sys-
tematic reviews of adolescent obesity surgery (Aikenhead 2011;
Black 2013). Both reviews assessed the O’Brien 2010 study along-
side a heterogeneous mix of largely underpowered non-RCT stud-
ies. Both reviews employed an earlier and less extensive literature
search than the search undertaken for this review. The degree of
weight loss and improvements to health-related quality of life re-
ported in theO’Brien 2010 study also agree with those reported in
recent reviews of adult obesity surgery (Colquitt 2014; Gloy 2013;
Picot 2009). However, a much wider range of adverse events were
reported in both the adult reviews and recent adolescent reviews.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The aim of this review was to assess the effects of surgery for
treating obesity in children and adolescents, however, the ability to
address this was severely limited by the size of the current evidence
base. Whilst an overview of the considerations arising from the
included study are provided below, in isolation, this study does
not provide sufficient evidence to adequately inform practice.
Comparedwith a programof lifestyle treatment for obesity, laparo-
scopic gastric banding led to greater body weight loss in one well
conducted study that included 50 patients. However, this study
was limited to two years of follow-up, was based on just one small
Australian population and was conducted in a private hospital that
received funding from the manufacturer the gastric band. There
is currently insufficient evidence to make an informed judgement
about efficacy. Whilst one study identified the possible benefits of
surgery, there are not enough data to assess efficacy across popu-
lations from different countries, socioeconomic and ethnic back-
grounds, who may respond differently. There are also insufficient
data to examine possible variation according to gender, age, base-
line weight status and different surgical procedures.
Twenty-eight per cent of the surgery participants required a revi-
sional procedure. A wider range of adverse events, including mor-
tality were reported in other reviews of non-RCT surgical inter-
ventions for obese young people (Aikenhead 2011; Black 2013).
Unlike adults, surgery in children and adolescents requires addi-
tional considerations, such as a suitable multi-disciplinary paedi-
atric team, pubertal status and degree of physical maturation, the
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psychological and nutritional impact of surgery, capacity to con-
sent and undertake the required post operative lifestyle changes,
appropriate family support and parental consent (Pratt 2009).
Bariatric surgery for young people, as for adults, should not be
viewed as a quick fix to weight loss but should be undertaken with
due diligence. O’Brien 2010 states that optimal effectiveness re-
quires long term specialist supportive follow-up, with considera-
tion required for the bespoke needs of an adolescent population.
Implications for research
This systematic review highlights the lack of randomised con-
trolled trials in this field. More high quality studies are required to
address the efficacy of bariatric surgery for the treatment obesity
in children and adolescents. The four ongoing studies, once com-
pleted, will provide additional evidence on bioenteric intragastric
balloon and gastric bypass as alternative procedures in Australian
and Swedish adolescents respectively, with two further European
studies examining gastric banding. It is important for future stud-
ies to address clinical effectiveness across a range of populations,
including participants ranging in socio-demographics, ethnicity,
baseline weight status and geography. Future studies should as-
sess the impact of the surgical procedure and post operative care
to minimise adverse events, including the need for post operative
adjustments and revisional surgery. Long term follow-up is also
critical to comprehensively assess the impact of surgery as partic-
ipants enter adulthood. Additional data on cost effectiveness and
participants views will also provide constructive evidence to help
steer future policy and practice decision making.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [author-defined order]
O’Brien 2010
Methods Parallel randomised control trial (RCT)
Randomisation ratio: 1:1
Superiority design
Participants Inclusion criteria: age between 14 and 18 years; BMI > 35, identifiable medical com-
plications such as hypertension, metabolic syndrome, asthma, back pain; physical lim-
itations such as an inability to play a sport, difficulties with activities of daily living;
or psychosocial difficulties such as isolation or low self-esteem, subject to bullying that
stems from obesity and evidence of attempts to lose weight by lifestyle means for more
than 3 years
Key inclusion criteria specified in study register (ACTRN12605000160639): “Have
a body mass index greater than 35 kg/m2 corrected for age, that is a z-score of 3.0 or
greater, have had identifiable problems with obesity for more than 3 years, self-motivated
with a good grasp of English and able to clearly understand the nature of a randomized
treatment program, be able to understand the options and study requirements and
comply with both of the management programs, be able to give informed consent to
either program, bewilling to be randomized, have the support of a parent or guardianwho
understands the nature and requirements of both treatment arms and is fully supportive
of the decision of the adolescent to enter the randomized study, willingness of the parent
or guardian to give informed consent to either arm. The subject and parent or guardian
partners would understand the requirements of the study itself, including the need for
serial simple anthropometric measurements, completion of serial questionnaires and
serial biochemical analysis that requires fasting venous sampling.”
Exclusion criteria: applicantswere excludedwhohad learningdisabilities and the Prader-
Willi syndrome
Key exclusion criteria specified in study register (ACTRN12605000160639): “Lack
of acceptance of the randomizationprocess, history of previous criteria abdominal surgery
which would potentially preclude laparoscopic placement of the band, a history of previ-
ous obesity surgery, any contraindication to Lap-Band placement history of previous ab-
dominal surgery which would potentially preclude laparoscopic placement of the band,
unsuitability for the Active8 peer support program, medical issues which contraindicated
the application of either arm of the study (these would include; acute myocardial in-
farction within the past 6 months, dementia, active psychosis, concurrent experimental
drug use, autoimmune disease, pregnancy, lactation, illicit drug use, excessive alcohol
intake, use of drugs known to affect body composition, cytotoxic drugs, internal ma-
lignancy or major organ failure) , systemic lupus erythematosus or other auto-immune
disease, direct hypothalamic damage as a cause of obesity, inability to understand the
risks, realistic benefits and compliance requirements of the Lap-Band intervention and
conventional management of severe obesity, Prader-Willi syndrome or other syndromes
associated with intellectual disability or hyperphagia”
Diagnostic criteria: obesity defined as BMI > 35
Interventions Number of study centres: consultations and adjustments of the gastric banding were
carried out at a community clinic dedicated to obesitymanagement or at a special clinic at
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O’Brien 2010 (Continued)
the Centre for Adolescent Health, Royal Children’s Hospital; gastric banding procedures
were conducted at a private hospital
Treatment before study: see run-in period.
Intervention (gastric banding program): “participants in the gastric banding group had
the procedure performedwithin amonth of randomization. The LAP-BANDAdjustable
Gastric Banding system (Allergan, Irvine, California) was used in all cases. Detailed
instructions on the requirements for correct eating and exercise after gastric banding
were provided by discussion as well as in written form before the procedure. Eating rules
centered on having 3 or fewer small (approximately 125 mL), protein-containing meals
per day, eaten slowly (1 min/bite) and chewed well. Each participant was encouraged to
undertake at least 30 minutes of formal exercise per day and to maintain a high level of
activity through the day. Clinical reviews were conducted approximately every 6 weeks
for 2 years by experienced medical staff. Adjustments to the volume of fluid in the band
were conducted in the office, without use of x-ray imaging, based on weight loss, sense
of satiety, and eating pattern and symptoms”
Comparator (lifestyle programme): “program centered on reduced energy intake (in-
dividualized diet plans ranging between 800 and 2000 kcal/d, depending on age and
weight status), increased activity (target of 10 000 steps per day on pedometer) with a
structured exercise schedule of at least 30 minutes a day and behavioral modification.
Compliance was monitored intermittently with food diaries and step counts. Consulta-
tion occurred approximately every 6 weeks throughout the 24-month study period by an
adolescent physician and a dietitian or exercise consultant, the study nurse coordinator,
and a sports medicine physician. The participant’s family was included in activities and
education where appropriate. Exercise and activity recommendations included decrease
of sedentary activities with a limit of 2-hour computer or television screen time, increase
of formal exercise including bicycle riding, walking, and swimming plus informal indi-
vidual and group activities. Group outings to fun parks, bike rides, hiking trips, walking,
jogging, kickboxing, indoor bowling, and outdoor reunions were scheduled. A personal
trainer was provided to each participant for a 6-week period. Parents were invited to
participate in a specific educational program that included sports motivational talks,
nutritional education, and discussions of the psychological aspects of adolescence”
Outcomes Outcomes reported in abstract of publication: number of participants which lost more
than 50% of excess weight, mean changes in weight loss, excess weight loss, BMI, BMI
z score change, number of participants with metabolic syndrome, quality of life, adverse
events
Study details Run-in period: “at initial telephone contact, potential participants and their families
were invited to attend a patient information session followed by a clinical assessment by
2 physicians experienced in the management of obesity in adolescents. At this time, the
nature of the study and the proposed management of the 2 study groups was carefully
explained, and the suitability of the participant was clarified. Participants were asked
to complete a 2-week food diary, record activity for 2 weeks using a pedometer, and
complete several questionnaires. A second consultation occurred no less than 4 weeks
later with a detailed clinical assessment, confirmation of satisfactory completion of the
tasks, and further discussion of the trial methods. Clinical assessment included measure-
ment of weight and height, neck, waist, and hip circumference; history of the weight
disorder; and diet and weight loss efforts. Clinical features of comorbidities of obe-
sity were sought. Laboratory analyses included fasting blood glucose, serum insulin, C-
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O’Brien 2010 (Continued)
peptide, hemoglobin A1c, iron status, liver function tests, lipids, and thyroid function
tests. Potential participants undertook a 2-month program that involved best practice
recommendations around eating and physical activity. At a third clinical appointment,
the randomization process was again explained and the consent form was signed by the
participant and the parent or guardian. After a cooling-off period of 7 days, the desire
to enter the study was reconfirmed ...”
Study terminated before regular end (for benefit / because of adverse events): no
Publication details Language of publication: English
Funding: commercial funding and non-commercial funding
Publication status: peer review journal
Stated aim for study Quote from publication: “we hypothesized that gastric banding would induce more
weight loss and would provide greater health benefits and better improvement in the
quality of life of obese adolescents than the optimal application of the currently available
lifestyle approaches. To test this hypothesis, we conducted a prospective, randomized
controlled trial in a group of severely obese adolescents”
Notes First author’s failure to report financial disclosure information was corrected in a letter
to the editor
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote from publication: “Randomiza-
tion was performed using a computer-de-
rived random allocation sequence to al-
low orderly admission into both programs.
There was no stratification or blocking,”
Information specified in study regis-
ter (ACTRN12605000160639): “Subjects
were block randomized into 3 unequal
blocks. Each block contained equal num-
bers in both treatment arms. The sequence
within blocks was determined by the staff
member in control of concealment by
drawing the allocation out of a hat and the
number in each blocking group was known
only to this staff member”
Comment: unclear risk because of mis-
match of information between publication
and study register
Allocation concealment (selection bias) Low risk Quote from author (via email): “The trial
coordinator went over the trial details with
the prospective participant (and parent)
, had the informed consent for the trial
signed, phoned the allocation centre, re-
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ceived the allocation and informed the par-
ticipant immediately”
Information specified in study regis-
ter (ACTRN12605000160639): “Inter-
vention recorded and stored in numbered,
sealed opaque envelopes organized and
maintained by staff member not involved
in patient care or scheduling and opened in
sequence as randomized.”
Comment: allocation was concealed
Baseline imbalance (chance bias) Low risk Comment: none detected
Blinding of participants and personnel
(performance bias)
Adverse events
High risk Quote from publication: “The study was
not blinded”
Information specified in study regis-
ter (ACTRN12605000160639): “Open
(masking not used)”
Comment: lack of blinding may pose a
high risk to this outcome measure
Blinding of participants and personnel
(performance bias)
BMI, weight loss, measures of body fat dis-
tribution
Unclear risk Quote from publication: “The study was
not blinded”
Information specified in study regis-
ter (ACTRN12605000160639): “Open
(masking not used)”
Comment:unclear if blindingwould affect
performance bias
Blinding of participants and personnel
(performance bias)
Health-related quality of life, self-esteem
High risk Quote from publication: “The study was
not blinded”
Information specified in study regis-
ter (ACTRN12605000160639): “Open
(masking not used)”
Comment: lack of blinding may pose a
high risk to this outcome measure
Blinding of participants and personnel
(performance bias)
Morbidity
Unclear risk Quote from publication: “The study was
not blinded”
Information specified in study regis-
ter (ACTRN12605000160639): “Open
(masking not used)”
Comment:unclear if blindingwould affect
performance bias
Blinding of outcome assessment (detection
bias)
Adverse events
High risk Quote from publication: “The study was
not blinded”
Comment: outcomes assessors were not
blinded, therefore detection bias may have
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occurred
Blinding of outcome assessment (detection
bias)
BMI, weight loss, measures of body fat dis-
tribution
Unclear risk Quote from publication: “The study was
not blinded”
Comment: outcomes assessors were not
blinded
Blinding of outcome assessment (detection
bias)
Health-related quality of life, self-esteem
High risk Quote from publication: “The study was
not blinded”
Comment: outcomes assessors were not
blinded, therefore detection bias may have
occurred
Blinding of outcome assessment (detection
bias)
Morbidity
Unclear risk Quote from publication: “The study was
not blinded”
Comment: outcomes assessors were not
blinded
Incomplete outcome data (attrition bias)
Adverse events
High risk Quote from publication: “We analysed
the weight change data according to the
patient’s randomly assigned program (in-
tention-to-treat analysis) and used com-
pleter’s analysis for the health and qual-
ity of life data”; “The laboratory and ques-
tionnaire represent data provided by only
those who completed”; “The laboratory
and questionnaire represent data provided
by only those who completed”; “All ob-
served data were considered for analysis,
with the mixed-effects models assuming
non informative dropout such that the
probability of dropout may depend on a
participant’s previous response but not on
current or future responses”
Comment: outcomes were assessed using
completers analysis
Incomplete outcome data (attrition bias)
BMI, weight loss, measures of body fat dis-
tribution
Low risk Quote from publication: “We analysed
the weight change data according to the pa-
tient’s randomly assigned program (inten-
tion-to-treat analysis) and used completer’s
analysis for the health and quality of life
data”; “The laboratory and questionnaire
represent data provided by only those who
completed”; “All observed data were con-
sidered for analysis, with the mixed-effects
models assuming non informative dropout
such that the probability of dropout may
depend on a participant’s previous response
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but not on current or future responses”
Comment: intention-to-treat analysis was
used, however this was for only one mea-
sured outcome (weight change) which was
the primary outcome measure
Incomplete outcome data (attrition bias)
Health-related quality of life, self-esteem
High risk Quote from publication: “We analysed
the weight change data according to the
patient’s randomly assigned program (in-
tention-to-treat analysis) and used com-
pleter’s analysis for the health and qual-
ity of life data”; “The laboratory and ques-
tionnaire represent data provided by only
those who completed”; “The laboratory
and questionnaire represent data provided
by only those who completed”; “All ob-
served data were considered for analysis,
with the mixed-effects models assuming
non informative dropout such that the
probability of dropout may depend on a
participant’s previous response but not on
current or future responses”
Comment: outcomes were assessed using
completers analysis
Incomplete outcome data (attrition bias)
Morbidity
Unclear risk Quote from publication: “We analysed
the weight change data according to the
patient’s randomly assigned program (in-
tention-to-treat analysis) and used com-
pleter’s analysis for the health and qual-
ity of life data”; “The laboratory and ques-
tionnaire represent data provided by only
those who completed”; “The laboratory
and questionnaire represent data provided
by only those who completed”; “All ob-
served data were considered for analysis,
with the mixed-effects models assuming
non informative dropout such that the
probability of dropout may depend on a
participant’s previous response but not on
current or future responses”
Comment: outcomes were assessed using
completers analysis
Selective reporting (reporting bias) Unclear risk Comment: mismatch between outcome
measures stated in trial register and publi-
cation
Other bias Low risk Comment: none detected
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Note: where the judgement is ’Unclear’ and the description is blank, the study did not report that particular outcome.
BMI: body mass index
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Aikenhead 2011 Systematic review
Black 2013 Systematic review
Farina 2012 Participants were adults
Gloy 2013 Systematic review
Picot 2009 Health-technology assessment report
Tyvonchuk 2009 Participants were ’young adults’; probably not a randomised controlled trial
Characteristics of ongoing studies [ordered by study ID]
ACTRN12609001004257
Trial name or title Title: randomised controlled trial of the Bioenterics Intragastric Balloon (BIB) versus lifestyle intervention
alone on weight loss and reversal of weight related diseases in obese adolescents
Acroynm: BIB study
Methods Type of study: interventional; randomised controlled trial
Allocation: randomised
Intervention model: parallel assignment
Masking: open
Primary purpose: treatment
Participants Condition: obesity
Enrollment: 50
Inclusion criteria: males and females aged 12 to 17 years; participants must be living in metropolitan
Perth and willing to attend outpatient appointments, and have no significant weight loss despite 3 months
attempted lifestyle improvements. Participants must also have a BMI Z-score >+3 or a BMI Z-score>+2 and
2 or more of the following co-morbidities: hyperlipidaemia; impaired glucose tolerance/hyperinsulinaemia;
hepatitis steatosis; hypertension; polycystic ovarian syndrome; obstructive sleep apnoea; benign intracranial
hypertension; degenerative joint disease
Exclusion criteria: previous gastrointestinal resections; structural abnormalities of the gastrointestinal tract;
psychiatric/eating disorder; rural dwelling; active oesophagitis (grade1) / active gastric ulcer or its previous
complications/hiatus hernia (> 5 cm); pregnancy; type 2 diabetes; patient on anticoagulants or non-steroidal
anti-inflammatory drugs gastric irritants, unwilling to make lifestyles changes or attend regular clinic ap-
pointments; unwilling to accept the probability of nausea and vomiting in the postoperative period; physical
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ACTRN12609001004257 (Continued)
inability to maintain regular follow-up; obstructive sleep apnoea requiring a continuous positive airway pres-
sure (CPAP) machine
Interventions Intervention: Bioenterics Intragastric Balloon (BIB) for a duration of six months, plus detailed post operative
dietary plan
Comparator: usual care multidisciplinary lifestyle intervention: changes in lifestyle are successful in part-
nership (CLASP) program. The program runs for 10 weeks (two and a half sessions held once a week) and
aims to achieve: a healthy diet, learning how to self-monitor, behavioural changes and improving physical
activities, through a series of participant and parent/guardian individual and group sessions
Outcomes Primary outcome: body mass index (BMI) raw score and Z score measured at baseline, six and 18 months
Secondary outcomes: biochemical tests, clinical symptoms and signs of obesity complications, assessed
through clinic visits andbiochemicalmarkers, fitness, physical activity and sedentary behaviour, using validated
questionnaires. Fitness will be assessed by the 6-minute walk test, step test and balance test, dietary habits
and intake changes, using a three-day food diary and an eating habits questionnaire, psychological scores on
validated questionnaires, blood pressure, measured using a handheld aneroid sphygmomanometer all assessed
at baseline, six and eighteenmonths. Tolerance and adverse events, including nausea, vomiting and abdominal
pain. This will be measured by assessing the postoperative requirement for antiemetics and documentation
of symptoms, measured at one week, two weeks, four weeks, 10 weeks, six months
Starting date 1/10/2009
Contact information Scientific queries to: Dr Jacqueline Curran
Princess Margaret Hospital for Children
Department of Endocrinology and Diabetes
Roberts Road
Subiaco, WA 6008
jacqueline.curran@health.wa.gov.au
Notes When identified the study was currently recruiting participants
Funding source: National Health and Medical Research Council
20 April 2015 (information from study authors): “Currently we have 23 in the control arm and 21 in the
intervention arm ... we will continue to recruit until 50”
NCT01172899
Trial name or title Title: bariatric surgery in children
Acroynm: BASIC
Methods Type of study: interventional; randomised controlled trial
Allocation: randomised
Intervention model: parallel assignment
Masking: single blind (outcomes assessor)
Primary purpose: treatment
Participants Condition: obesity; morbid
Enrollment: estimated 60
Inclusion criteria: aged 12 to 16 years; age and sex adjusted BMI > 40 kg/m2 or > 35 kg/m2 with associ-
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NCT01172899 (Continued)
ated comorbidity (associated comorbidity includes: glucose intolerance, type 2 diabetes, hypertension, pseu-
dotumour cerebri, acanthosis nigricans, obstructive sleep apnoea syndrome, depression, arthropathies, non-
alcoholic steatohepatitis and dyslipidaemia); > 1 year multidisciplinary organized weight reducing attempts
with less than 5% weight loss; demonstrate decisional capacity
Exclusion criteria: psychologically not suitable; pre-menarche or bone age <15 years in boys; obesity associ-
ated to other disorders such as hypothyroidism; syndromal disorders such as Prader-Willi syndrome; severe
cardiorespiratory impairment (ASA class 3 or higher); Insufficiently fluid in the Dutch language; unwilling-
ness to adhere to follow-up programmes
Interventions Intervention: laparoscopic gastric band placement + combined lifestyle interventions
Comparator: combined lifestyle interventions
Outcomes Primary outcome(s): weight loss, excess weight loss and loss of excess BMI
Secondary outcome(s): body composition; pubertal development; metabolic and endocrine changes; In-
flammatory status; cardiovascular abnormalities; non-alcoholic fatty liver disease; quality of life; behaviour
changes; operative complications; effects on sleep architecture; brain development; physical activity; behavior
towards food
Other outcome(s): not reported
Starting date Study start date: July 2010
Study completion date: December 2015 (final data collection date for primary outcome measure)
Contact information Responsible party/principal investigator: Maastricht University Medical Center.
LWE van Heurn, Professor: +31433877477. e.van.heurn@mumc.nl
Givan F Paulus, PhD student: +31620727692. g.paulus@mumc.nl.
Notes When the study was identified they were currently recruiting participants
ClinicalTrials.gov Identifier: NCT01172899.
Study sponsor: Maastricht University Medical Center
NCT01700738
Trial name or title Title: evaluation of the effects of laying early a gastric band on the prevention of morbid obesity randomized
checked against standard management of obesity in this population
Acronym: CHADO
Methods Type of study: interventional; randomised controlled trial
Allocation: randomised
Intervention model: parallel assignment
Masking: open label
Primary purpose: treatment
Participants Condition: obesity
Enrollment: estimated 200
Inclusion criteria: adolescents 12 to 16 years and with BMI and weight gain according to sex and age is
greater than IMCZ-score > 4 DP> 8 kg; obesity “common” non-syndromic; medical decision of surgical
placement of laparoscopic gastric banding; adolescent and family who understand and accept the need for
medical and surgical follow long term; adolescent and family who fully understood the oral and written
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information explaining the study and the need for prolonged follow-up; obtention of oral and written consent
of the adolescent and the parents; parents and adolescents affiliated with the social security system
Exclusion criteria: intellectual deficit; psychiatrics contraindication of surgical placement of laparoscopic
gastric banding; obesity with severe binge eating; pregnancy or wishes of pregnancy in the following year;
non accession adolescent and / or family in the process of medical care before inclusion; predictable post
surgical monitoring difficulties; suspicion of physical abuse, verbal or negligence / deficiency in care of the
family; participation in a clinical study evaluating a treatment during the 2 years of the study; anesthetic
contra indication for placement of a gastric laparoscopic; IMC > 50 kg/m² the day of inclusion
Interventions Intervention: gastric ring surgery
Comparator: nutritional help
Outcomes Primary outcome(s): BMI Z-score evolution in 2 years
Secondary outcome(s): evolution of quality of life scales; evolution of BMIZ-score; evaluation of alimentary
troubles and psychiatric troubles; evolution of round-waist; evolution of bodily composition; evolution of
metabolic syndrome parameters; evolution of respiratory parameters: polysomnography; determination of
success factors of the ring; study of tolerance of the gastric ring
Other outcome(s): not reported
Starting date Study start date: November 2012
Study completion date: November 2015
Contact information Responsible party/principal investigator: Regis Coutant, University Hospital of Angers. Email: re-
coutant@chu-angers.fr
Notes When the study was identified it was not yet open for participant recruitment
Study sponsor: University Hospital, Angers.
ClinicalTrials.gov Identifier:NCT01700738
NCT02378259
Trial name or title Title: randomized controlled trial; intensive conservative treatment or bariatric surgery for adolescents (13-
15 y) with severe obesity (AMOS-RCT)
Methods Type of study: interventional; randomised controlled trial
Allocation: randomised
Intervention model: parallel assignment
Masking: open label
Primary purpose: treatment
Participants Condition: obesity
Enrollment: estimated 50
Inclusion Criteria:
• Age 13-15 years
• BMI >35
• Failed comprehensive treatment for obesity > 1 year
• Passing assessment of psychologist
• Tanner stage 3 or more
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Exclusion Criteria:
• Monogenic obesity (for example Praeder Willis, Laurence Moon-Bardet-Biedl)
• Obesity secondary to brain injury
• Severely mentally disabled
• Not eligible for general anesthesia
• Psychotic or other major psychiatric illness
• Previous major gastrointestinal surgery
Interventions Intervention: Roux-en-Y gastric bypass surgery
Comparator: intensive conservative treatment
Outcomes Primary outcome measures: body mass index (time frame: 2, 7, 12 and 17 years after treatment initiation)
Secondary outcome measures:
Metabolic control (time frame: 2, 7, 12 and 17 years after treatment initiation); glucose control (fP-Glc, fs-
Insulin, HbA1c, oral glucose tolerance test); blood lipids (HDL, LDL, TG, Apo A, Apo B); blood pressure
(systolic and diastolic); inflammation (LPK, CRP, Adiponectin, IL-6, TNF-alfa); liver function tests (AST,
ALT, ALP, Bil)
Quality of life (time frame: 2, 7, 12 and 17 years after treatment initiation), mental and physical QoL
Socioeconomic development (time frame: 7, 12 and 17 years after treatment initiation), education, civil
status, number of children, income, sick leave (from national registries)
Health care consumption (time frame: 2, 7, 12 and 17 years after treatment initiation), in-hospital care,
outpatient care, prescribed medications (from national registries)
Skeletal maturation and quality (time frame: 2, 7, 12 and 17 years after treatment initiation), bone mineral
content and bone mineral density will be assessed as well as blood markers for bone formation and resorption
Addictive behavior (time frame: 2, 7, 12, 17 years after treatment initiation), alcohol consumption, blood
markers for alcohol consumption, drugs, brain response to visual stimuli
Mental health (time frame: 2, 7, 12 and 17 years after treatment initiation ] [ Designated as safety issue:
Yes ]Depression, anxiety, self esteem, stability in neuropsychiatric disease (ADHD, ADD), psychiatric illness,
OCD
Adverse events (time frame: 2, 7, 12 and 17 years after treatment initiation), any adverse event (physical,
mental or other)
Eating function (time frame: 2, 7, 12 and 17 years after treatment initiation), assessment of meal pattern,
dietary composition and gastrointestinal symptoms in relation to eating
Energy expenditure (time frame: 2 and 7 years after treatment initiation, doubly labelledwater, basicmetabolic
rate, 24h energy expenditure chamber after 7 years
Other outcome measures: cancer or precancerous lesions (time frame: 17 years after treatment initiation
and later), as this parameter is hard to foresee we might need to extend the time for assessment longer than
17 years
Starting date Study start date: August 2015
Study completion date: May 2021
Contact information Responsible party/principal investigator: Torsten Olbers, Göteborg University
Notes When identified this study was not yet recruiting participants
Study sponsor: Göteborg University
Clinical trials identifier: NCT02378259
Other study ID number: 578-13
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D A T A A N D A N A L Y S E S
This review has no analyses.
A D D I T I O N A L T A B L E S
Table 1. Overview of study populations
Interven-
tion(s)
and com-
parator(s)
Sample
sizea
Screened/
eligible
[N]
Ran-
domised
[N]
Safety
[N]
ITT/anal-
ysed [N]
Finishing
study
[N]
Ran-
domised
finishing
study
[%]
Follow-up
b
O’Brien
2010
I: gas-
tric band-
ing proce-
dure
+ lifestyle
advice
The
study was
powered
assuming
that,
using an
intention-
to treat
analysis,
more than
60% of
patients of
the gastric
banding
group
would
achieve
an excess
weight loss
of more
than 50%
at 2 years
and that
less than
10% of the
lifestyle
group
would
achieve
this weight
lossc . Us-
ing these
expected
propor-
tions,
study
163/84 25 25 25/25d 24 96 24 months
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Table 1. Overview of study populations (Continued)
authors
required
17 par-
ticipants
in each
the study
group to
provide
an 80%
power and
a 2-sided
P value of
0.05. On
the basis of
a possible
loss of
30% after
randomi-
sation, 50
adoles-
cents were
recruited
C: lifestyle
pro-
gramme
25 25 25/25d 18 72
total: 50 50 50/50 42 84
Grand to-
tal
All inter-
ventions
25 24
All c om-
parators
25 18
All inter-
ventions
and c om-
parators
50 42
aAccording to power calculation in study publication or report
bDuration of intervention or follow-up, or both, under randomised conditions until end of study
cActual numbers were 84% in the intervention and 12% in the comparator group
dPrimary analysis only (weight change data)
“-” denotes not reported
ITT: intention-to-treat
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A P P E N D I C E S
Appendix 1. Search strategies
Cochrane Library (Wiley)
#1 [mh Ôbesity]
#2 [mh ˆ“Obesity, Morbid”]
#3 [mh ˆ“Obesity, Abdominal”]
#4 [mh ˆ“Pediatric Obesity”]
#5 [mh Ôverweight]
#6 [mh ˆ“Weight Loss”]
#7 (adipos* or obes*):ti,ab,kw
#8 (overweight* or “over weight*”):ti,ab,kw
#9 (“weight” near/4 (reduc* or los* or control* or gain*)):ti,ab,kw
#10 (“body mass ind*” or “BMI” or “waist hip ratio” or “skinfold thickness”):ti,ab,kw
#11 {or #1-#10}
#12 [mh ˆ“Bariatric Surgery”]
#13 [mh ˆ“Gastric Bypass”]
#14 [mh ˆGastroplasty]
#15 [mh ˆ“Jejunoileal Bypass”]
#16 [mh ˆLipectomy]
#17 [mh ˆGastroenterostomy]
#18 [mh ˆGastrectomy]
#19 [mh ˆ“Biliopancreatic Diversion”]
#20 [mh ˆ“Gastric Balloon”]
#21 [mh ˆ“Vagotomy, Truncal”]
#22 [mh ˆStomach/SU]
#23 [mh ˆ“Anastomosis, Roux-en-Y”]
#24 [mh ˆLaparoscopy]
#25 ((obes* or “weight loss” or “weight reduction” or antiobes* or “metabolic” or “gastric” or laparoscop*) next surg*):ti,ab,kw
#26 (“bariatric” next (surg* or operation* or procedure*)):ti,ab,kw
#27 (surg* next (procedure* or intervention* or treatment* or “management”)):ti,ab,kw
#28 (“gastric” near/4 (band* or imbrication* or plication* or “sleeve” or stapl* or resection* or reduction* or “stimulation”)):ti,ab,kw
#29 ((“gastroileal” or “jejunoileal” or “biliopancreatic” or “gastric” or “stomach”) next “bypass”):ti,ab,kw
#30 gastrojejunostom*:ti,ab,kw
#31 gastrectom*:ti,ab,kw
#32 gastroplast*:ti,ab,kw
#33 “biliopancreatic diversion”:ti,ab,kw
#34 (malabsorpti* next (procedure* or surg*)):ti,ab,kw
#35 “lap band”:ti,ab,kw
#36 “LAGB”:ti,ab,kw
#37 “LSG”:ti,ab,kw
#38 (RYGB* or “roux en y”):ti,ab,kw
#39 “duodenal switch”:ti,ab,kw
#40 “stomach stapl*”:ti,ab,kw
#41 “scopinaro”:ti,ab,kw
#42 ((“mason” or “rose” or “stomaphyx”) next “procedure”):ti,ab,kw
#43 ((“gastric” or “intragastric”) next balloon*):ti,ab,kw
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(Continued)
#44 ((“endoluminal” or “bypass”) next “sleeve”):ti,ab,kw
#45 “endobarrier”:ti,ab,kw
#46 “truncal vagotomy”:ti,ab,kw
#47 {or #12-#46}
#48 #11 and #47
#49 [mh Âdolescent]
#50 [mh ˆChild]
#51 [mh ˆ“Young Adult”]
#52 [mh ˆPediatrics]
#53 “minors”:ti,ab,kw
#54 (“boy” or “boys” or “boyhood”):ti,ab,kw
#55 girl*:ti,ab,kw
#56 (“kid” or “kids”):ti,ab,kw
#57 (child* or schoolchild*):ti,ab,kw
#58 adolescen*:ti,ab,kw
#59 juvenil*:ti,ab,kw
#60 youth*:ti,ab,kw
#61 (teen* or preteen*):ti,ab,kw
#62 (underage* or “under age*”):ti,ab,kw
#63 pubescen*:ti,ab,kw
#64 (paediatric* or pediatric*):ti,ab,kw
#65 {or #49-#64}
#66 #48 and #65
MEDLINE (Ovid SP)
1 Obesity/
2 Obesity, Morbid/
3 Obesity, Abdominal/
4 Pediatric Obesity/
5 Overweight/
6 Weight Loss/
7 (adipos* or obes*).tw.
8 (overweight* or over weight*).tw.
9 (weight adj3 (reduc* or los* or control* or gain*)).tw.
10 (body mass ind* or BMI or waist hip ratio or skinfold thickness).tw.
11 or/1-10
12 Bariatric Surgery/
13 Gastric Bypass/
14 Gastroplasty/
15 Jejunoileal Bypass/
16 Lipectomy/
17 Gastroenterostomy/
18 Gastrectomy/
19 Biliopancreatic Diversion/
20 Gastric Balloon/
21 Vagotomy, Truncal/
22 Stomach/su [Surgery]
23 Anastomosis, Roux-en-Y/
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(Continued)
24 Laparoscopy/
25 ((obes* or weight loss or weight reduction or antiobes* or metabolic or gastric or laparoscop*) adj1 surg*).tw.
26 (bariatric adj1 (surg* or operation? or procedure?)).tw.
27 (surg* adj1 (procedure? or intervention? or treatment? or management)).tw.
28 (gastric adj3 (band* or imbrication? or plication? or sleeve or stapl* or resection? or reduction? or stimulation)).tw.
29 ((gastroileal or jejunoileal or biliopancreatic or gastric or stomach) adj1 bypass).tw.
30 gastrojejunostom*.tw.
31 gastrectom*.tw.
32 gastroplast*.tw.
33 biliopancreatic diversion.tw.
34 (malabsorpti* adj1 (procedure* or surg*)).tw.
35 lap band.tw.
36 LAGB.tw.
37 LSG.tw.
38 (RYGB* or roux en y).tw.
39 duodenal switch.tw.
40 stomach stapl*.tw.
41 scopinaro.tw.
42 ((mason or rose or stomaphyx) adj1 procedure).tw.
43 ((gastric or intragastric) adj1 balloon).tw.
44 ((endoluminal or bypass) adj1 sleeve).tw.
45 endobarrier.tw.
46 truncal vagotomy.tw.
47 or/12-46
48 11 and 47
[49-65 Ovid SP adaptation of pediatric filter for PubMed by Leclercq 2013]
49 Adolescent/
50 Child/
51 Young Adult/
52 Pediatrics/
53 minors.tw.
54 (boy or boys or boyhood).tw.
55 girl*.tw.
56 (kid or kids).tw.
57 (child* or schoolchild*).tw.
58 adolescen*.tw.
59 juvenil*.tw.
60 youth*.tw.
61 (teen* or preteen*).tw.
62 (underage* or under age*).tw.
63 pubescen*.tw.
64 p?ediatric*.tw.
65 or/49-64
66 48 and 65
[Lefebvre 2011Cochrane Handbook 2008 RCT filter - sensitivity maximizing version, without “drug therapy.fs”]
67 randomized controlled trial.pt.
68 controlled clinical trial.pt.
69 randomi?ed.ab.
70 placebo.ab.
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(Continued)
71 randomly.ab.
72 trial.ab.
73 groups.ab.
74 or/67-73
75 exp animals/ not humans/
76 74 not 75
77 66 and 76
PubMed
#1 adipos*[tw] OR obes*[tw] OR overweight*[tw] OR over weight*[tw] OR weight reduc*[tw] OR weight los*[tw] OR weight
control*[tw] OR weight gain*[tw]
#2 bariatric[tw] OR gastric[tw] OR band*[tw] OR sleeve*[tw] OR resection*[tw] OR jejunoileal[tw] OR biliopancreatic[tw] OR
bypass[tw] OR gastrojejunostom*[tw] OR gastrectom*[tw] OR gastroplast*[tw] OR malabsorpti*[tw] OR “lap band”[tw] OR
LAGB[tw] OR LSG[tw] OR RYGB*[tw] OR “roux en y”[tw] OR “duodenal switch”[tw] OR stomach stapl*[tw] OR balloon*[tw]
OR endobarrier[tw] OR “truncal vagotomy”[tw]
#3 #1 AND #2
#4minors[tw]ORboy[tw]ORboys[tw]ORboyhood[tw]OR girl*[tw]ORkid[tw]OR kids[tw]OR child*[tw]OR schoolchild*[tw]
OR adolescen*[tw] OR juvenil*[tw] OR youth*[tw] OR teen*[tw] OR preteen*[tw] OR underage*[tw] OR under age*[tw] OR
pubescen*[tw] OR paediatric*[tw] OR pediatric*[tw]
#5 #3 AND #4
#6 #5 not medline[sb] not pmcbook
EMBASE (Ovid SP)
1 Obesity/
2 Morbid Obesity/
3 Abdominal Obesity/
4 Childhood Obesity/
5 Overnutrition/
6 Weight Reduction/
7 (adipos* or obes*).tw.
8 (overweight* or over weight*).tw.
9 (weight adj3 (reduc* or los* or control* or gain*)).tw.
10 (body mass ind* or BMI or waist hip ratio or skinfold thickness).tw.
11 or/1-10
12 Bariatric Surgery/
13 Biliopancreatic Bypass/
14 Gastric Banding/
15 Sleeve Gastrectomy/
16 Stomach surgery/
17 Gastrectomy/
18 Stomach Bypass/
19 Gastroenterostomy/
20 Intestine Bypass/
21 Jejunoileal Bypass/
22 Intestine anastomosis/
23 Roux Y anastomosis/
24 Gastroenterostomy/
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(Continued)
25 Lipectomy/
26 Gastric Balloon/
27 Gastric Band/
28 Truncus vagotomy/
29 ((obes* or weight loss or weight reduction or antiobes* or metabolic or gastric or laparoscop*) adj1 surg*).tw.
30 (bariatric adj1 (surg* or operation? or procedure?)).tw.
31 (surg* adj1 (procedure? or intervention? or treatment? or management)).tw.
32 (gastric adj3 (band* or imbrication? or plication? or sleeve or stapl* or resection? or reduction? or stimulation)).tw.
33 ((gastroileal or jejunoileal or biliopancreatic or gastric or stomach) adj1 bypass).tw.
34 gastrojejunostom*.tw.
35 gastrectom*.tw.
36 gastroplast*.tw.
37 biliopancreatic diversion.tw.
38 (malabsorpti* adj1 (procedure* or surg*)).tw.
39 lap band.tw.
40 LAGB.tw.
41 LSG.tw.
42 (RYGB* or roux en y).tw.
43 duodenal switch.tw.
44 stomach stapl*.tw.
45 scopinaro.tw.
46 ((mason or rose or stomaphyx) adj1 procedure).tw.
47 ((gastric or intragastric) adj1 balloon).tw.
48 ((endoluminal or bypass) adj1 sleeve).tw.
49 endobarrier.tw.
50 truncal vagotomy.tw.
51 or/12-50
52 11 and 51
53 Juvenile/
54 Adolescent/
55 Child/
56 Young adult/
57 Pediatrics/
58 minors.tw.
59 (boy or boys or boyhood).tw.
60 girl*.tw.
61 (kid or kids).tw.
62 (child* or schoolchild*).tw.
63 adolescen*.tw.
64 juvenil*.tw.
65 youth*.tw.
66 (teen* or preteen*).tw.
67 (underage* or under age*).tw.
68 pubescen*.tw.
69 p?ediatric*.tw.
70 or/53-69
71 52 and 70
[Wong 2006“sound treatment studies” filter - BS version]
72 random*.tw. or clinical trial*.mp. or exp health care quality/
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(Continued)
73 71 and 72
74 limit 73 to embase
LILACS (IAHx)
(MH:“Bariatric Surgery” OR MH:“Gastroenterostomy” OR MH:“Obesity/surgery” OR MH:“Obesity, Morbid/surgery” OR MH:
“Obesity, Abdominal/surgery” OR ((bariatric$ OR obes$ OR gastric$) AND (surg* OR cirug* OR cirurg*)) OR (gastr$ AND (band$
OR bypass OR sleeve OR vertic$ OR derivac$)) OR gastrojejun$ OR (biliopancreatic AND (diversion OR derivac$ OR bypass))
OR gastroplast$) AND (MH:“Adolescent” OR MH:“Child” OR MH:“Young Adult” OR MH:“Pediatrics” OR boy OR boys OR
girl$ OR kid OR kids OR child$ OR schoolchild$ OR adolescen$ OR juvenil$ OR youth$ OR teen$ OR preteen$ OR underage$
OR pubescen$ OR paediatri$ OR pediatri$ OR joven$ OR jovem$ OR juvenil$ OR niños OR niñas OR criancas OR menin$)
+ Filter “Controlled Clinical Trial”
ICTRP trial register (Standard search)
bariatric AND child* OR
bariatric AND adolesc* OR
bariatric AND young* OR
obes* AND surg* AND child* OR
obes* AND surg* AND adolesc* OR
obes* AND surg* AND young* OR
obes* AND bypass* AND child* OR
obes* AND bypass* AND adolesc* OR
obes* AND bypass* AND young* OR
obes* AND gastr* AND child* OR
obes* AND gastr* AND adolesc* OR
obes* AND gastr* AND young* OR
obes* AND biliopancreatic AND child* OR
obes* AND biliopancreatic AND adolesc* OR
obes* AND biliopancreatic AND young* OR
obes* AND jejuno* AND child* OR
obes* AND jejuno* AND adolesc* OR
obes* AND jejuno* AND young* OR
obes* AND band* AND child* OR
obes* AND band* AND adolesc* OR
obes* AND band* AND young* OR
obes* AND endoluminal AND child* OR
obes* AND endoluminal AND adolesc* OR
obes* AND endoluminal AND young* OR
obes* AND endobarrier AND child* OR
obes* AND endobarrier AND adolesc* OR
obes* AND endobarrier AND young*
ClinicalTrials.gov trial register (Advanced search)
Conditions: adiposity OR adipose OR obese OR obesity OR overweight OR “over weight”
Interventions: surgery OR surgical OR bariatric OR gastroenterostomy OR gastrojejunostomy OR gastrectomy OR gastroplasty
OR gastric OR band OR banding OR balloon OR roux OR lipectomy OR bypass OR LAGB OR LSG OR RYGB OR duodenal
OR sleeve OR endobarrier
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(Continued)
Age Group: Child
Appendix 2. Description of interventions
Intervention(s) Comparator(s)
O’Brien 2010 Gastric banding procedure (LAP-BAND® adjustable
gastric banding system)
Lifestyle advice (eating rules and physical activity)
Lifestyle program (dietary and exercise advice (assessed by
pedometers and food diary), behavioural modification,
group outings and a personal trainer for 6 weeks)
Appendix 3. Baseline characteristics (I)
Interven-
tion(s)
and com-
parator(s)
Dura-
tion of in-
tervention
(dura-
tion of fol-
low-up)
Partici-
pat-
ing popu-
lation
Study pe-
riod
[year to
year]
Country Setting Duration
of obesity
[mean
years (SD)
]
Comed-
ications /
Cointer-
ventions
Comor-
bidities
O’Brien
2010
I: gas-
tric band-
ing proce-
dure
+ lifestyle
advice
After
the proce-
dure clini-
cal reviews
were con-
ducted ap-
prox-
imately ev-
ery 6 weeks
for 2 years
(24
months)
Severely
obese ado-
lescents
with iden-
tifi-
able medi-
cal compli-
cations,
physical
limitations
or psy-
chosocial
difficulties
May 2005
to Septem-
ber 2008
Mel-
bourne,
Australia
Commu-
nity clinic
or Centre
for Adoles-
cent
Health,
Royal
Children’s
Hospital
Gastric
banding
procedures
were con-
ducted at a
private
hospital
- - Iden-
tifiable
medical
complica-
tions such
as hyper-
tension,
metabolic
syndrome,
asthma,
back pain;
physical
limitations
such as an
inability
to play
a sport,
difficul-
ties with
activities
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of daily
living; psy-
chosocial
difficulties
such as
isolation
or low self-
esteem,
and sub-
ject to bul-
lying that
stems from
obesity
C: lifestyle
pro-
gramme
Consul-
tation oc-
curred ap-
prox. every
6 weeks
through-
out the 24-
month
study pe-
riod; a per-
sonal
trainer was
provided
to each
partic-
ipant for a
6-week pe-
riod
(24
months)
“-” denotes not reported
C: comparator; I: intervention; SD: standard deviation
Appendix 4. Baseline characteristics (II)
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Interven-
tion(s)
and com-
parator(s)
Sex
[female
%]
Age
[mean
years (SD)
]
BMI
[mean kg/
m² (SD)]
BMI z-
score
(SD)
Weight
[mean kg
(SD)]
Waist cir-
cumfer-
ence
[mean cm
(SD)]
BP
systolic
[mean
mm Hg
(SD)]
BP
diastolic
[mean
mm Hg
(SD)]
O’Brien
2010
I: gas-
tric band-
ing proce-
dure
+ lifestyle
advice
64 16.5 (1.4) 42.3 (6.1) 2.54 (0.
31)
120.7 (25.
3)
120.8 (14.
2)
122 (14) 72 (8)
C: lifestyle
pro-
gramme
72 16.6 (1.2) 40.4 (3.1) 2.46 (0.
22)
115.4 (14.
0)
118.1 (10.
6)
133 (16) 77 (11)
“-” denotes not reported
BMI: body mass index; BMI z-score (BMI standard deviation score): measure of relative weight adjusted for child age and sex; BP:
blood pressure; C: comparator; I: intervention; SD: standard deviation
Appendix 5. Matrix of study endpoints (publications and trial documents)
Endpoints quoted in trial
document(s)
(ClinicalTrials.gov, FDA/
EMA document, manu-
facturer’s web site, pub-
lished design paper)a
Study results posted in
trial register (publica-
tions specified in trial reg-
ister)
Endpoints quoted in
publication(s)b,c
Endpoints quoted in ab-
stract of publication(s)b,c
O’Brien 2010 Source: AC-
TRN12605000160639
(retrospectively registered)
Primary outcome mea-
sure(s):
at the end of the 2-year
period following random-
ization: % of participants
who achieve a weight loss
of 50% of excess BMI cor-
rected for age; the initial
BMI will be adjusted for
age (z-score)
No (yes - O’Brien 2010) Primary outcome mea-
sure(s): the primary end-
point was whether partic-
ipants could lose 50% ex-
cess weight
Primary outcome mea-
sure(s):
weight loss (% loss of ex-
cess weight, kg, BMI, BMI
z-score)
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(Continued)
Secondary outcome mea-
sure(s):
dif-
ference in weight, height,
skinfolds at triceps, min-
imal abdominal, maximal
gluteal circumferences and
neck circumference at the
upper border of the thyroid
cartilage (at 24 months);
functional
status using SF36, multi-
dimensional body-self re-
lation questionnaire, Beck
depression inventory, child
health questionnaire, binge
eating scale, step fitness
(pedometers) - at 6,12, and
24 months;
relationship of primary
outcomewithUniversity of
Rhode Island change as-
sessment (URICA) scale -
at 2 years;
changes in comorbidities
(including hypertension,
impaired fasting glucose,
hyperinsulinaemia, insulin
resistance and pancreatic
beta cell function, dyslipi-
daemia, clinical polycystic
ovary syndrome, markers
for obesity related liver dys-
function (NAFLD), ob-
structive sleep apnoea, ex-
cessive daytime sleepiness
and asthma) - at 6,12 and
24 months;
side effects of treatment
with emphasis on compli-
ance, peri-operative prob-
lems, postoperative vomit-
ing, need for revisional pro-
cedures, cost of therapy for
both arms - at 24 months
Secondary outcome mea-
sure(s):
health (health status was
documented by clinical
assessment and investiga-
tions at the initial assess-
ment before randomiza-
tion, and at 12 and 24
months after randomiza-
tion); quality of life (using
the child health question-
naire (CHQ CF-50); ad-
verse events resulting from
treatment or from failure of
compliance with the proto-
col
Secondary outcome mea-
sure(s):
metabolic syndrome, qual-
ity of life, adverse outcomes
Other outcome measure
(s):
-
Other outcome measure
(s):
total weight loss (kg), per-
Other outcome measure
(s):
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centage of total weight
lost, percentage of excess
weight lost, change in BMI
and BMI z score; an-
thropometric measures in-
cluded neck, waist, and hip
circumference; metabolic
syndrome (defined by the
age-specific adolescent cri-
teria of Joliffe and Janssen
linked to the Adult Treat-
ment Panel III 21 criteria)
; hypertension (adjusted
for age); insulin sensitivity
and pancreatic -cell func-
tion (homeostatic model
assessment (HOMA); ad-
verse events included pe-
rioperative complications,
revisional or other gastric
bandingprocedures, proto-
col violations, adverse drug
or treatment effects, hospi-
talizations, new disease di-
agnoses, and loss to follow-
up
- denotes not reported
aTrial document(s) refers to all available information from published design papers and sources other than regular publications (e.g.
FDA/EMA documents, manufacturer’s web sites, trial registers)
bPublication(s) refers to trial information published in scientific journals (primary reference, duplicate publications, companion
documents or multiple reports of a primary study)
cOther outcome measures refer to all outcomes not specified as primary or secondary outcome measures
BMI: body mass index; EMA: European Medicines Agency; FDA: Food and Drug Administration (US)
Appendix 6. Examination of outcome reporting bias according to ORBIT classification
Outcome High risk of bias
(category A)a
High risk of bias
(category D)b
High risk of bias
(category E)c
High risk of bias
(category G)d
O’Brien 2010 N/A
aClear that outcome was measured and analysed; trial report states that outcome was analysed but only reports that result was not
significant
(Classification ’A’, table 2, Kirkham 2010)
bClear that outcome was measured and analysed; trial report states that outcome was analysed but no results reported
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( Classification ’D’, table 2, Kirkham 2010)
cClear that outcome was measured; clear that outcome was measured but not necessarily analysed; judgement says likely to have been
analysed but not reported because of non-significant results
(Classification ’E’, table 2, Kirkham 2010)
dUnclear whether the outcome was measured; not mentioned but clinical judgement says likely to have been measured and analysed
but not reported on the basis of non-significant results
(Classification ’G’, table 2, Kirkham 2010)
N/A: not applicable
Appendix 7. Definition of endpoint measurement (I)
Body mass in-
dex
Adverse events Health-re-
lated quality of
life and self es-
teem
All-cause mor-
tality
Morbidity
O’Brien 2010 Ex-
pressed as change
in BMI (kg/m²)
and BMI z score
(reference: Cen-
ters for Disease
Control and Pre-
vention (CDC)
growth charts)
Adverse events
included periop-
erative complica-
tions,
re-
visional or other
gastric banding
procedures,
pro-
tocol violations,
adverse drug or
treatment effects,
hospitalisations,
new disease diag-
noses, and loss
to follow-up.
A serious/severe
adverse event was
not defined
Quality of Life
- measured using
the Child Health
Questionnaire
(CHQ CF-50)
The question-
naire was admin-
istered to each
adolescent alone,
prior to ran-
domisation, and
at 2 years af-
ter entry. The
CHQCF-50 has
11 validated sub-
scores. Each item
was scored and
transformed into
10final subscores
with values rang-
ing from 0 to
100, and 1 sub-
score (change of
health) with 5
levels
N/I Health status was
documented
by clinical assess-
ment and inves-
tigations at the
initial assessment
before randomi-
sation, and at 12
and 24 months
after randomi-
sation: metabolic
syndrome, de-
fined by the age-
specific
adolescent crite-
ria linked to the
Adult Treatment
Panel III hyper-
tension was ad-
justed to age and
defined using the
2004 report
of the National
High Blood Pres-
sure Ed-
ucation Program
Working Group
on High Blood
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Pressure in Chil-
dren and Adoles-
cents
BMI: body mass index; BMI z-score (BMI standard deviation score): measure of relative weight adjusted for child age and sex; N/D:
not defined; N/I: not investigated
Appendix 8. Definition of endpoint measurement (II)
Measures of body fat dis-
tribution
Behaviour change Participants views of the in-
tervention
Socioeconomic effects
O’Brien 2010 Anthropometric measures
included neck, waist, and
hip circumference - no ref-
erence;
total weight loss (kg), per-
centage of total weight lost
N/I N/I N/I
N/D: not defined; N/I: not investigated
Appendix 9. Adverse events (I)
Interven-
tion(s)
and com-
parator(s)
Ran-
domised
or sa-
fety popu-
lation
[N]
Deaths
[N (%)]
Partici-
pants
with reop-
erations
[N]
Partici-
pants
with reop-
erations
[%]
Partici-
pants with
adverse
events
[N]
Partici-
pants with
adverse
events
[%]
Partici-
pants with
severe/se-
rious ad-
verse
events
[N(%)]
Partic-
ipants dis-
contin-
uing study
due to ad-
verse
events
O’Brien
2010
I: gas-
tric band-
ing proce-
dure
+ lifestyle
program
25 0 (0) 7 28 12 48 - 0 (0)
C: lifestyle
pro-
gramme
25 0 (0) N/A N/A 11 44 - 0 (0)
47Surgery for the treatment of obesity in children and adolescents (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
all: 50 0 (0) N/A N/A 23 46 - 0 (0)
“-” denotes not reported
C: comparator; I: intervention; N/A: not applicable
Appendix 10. Adverse events (II)
Intervention
(s) and com-
parator(s)
Randomised
or safety pop-
ulation
[N]
Participants
hospitalised
[N]
Participants
hospitalised
[%]
Par-
ticipants with
specific ad-
verse events
[description]
Par-
ticipants with
specific ad-
verse events
[N]
Par-
ticipants with
specific ad-
verse events
[%]
O’Brien 2010 I:
gastric band-
ing procedure
+ lifestyle pro-
gram
25 9 36 (1) Proxi-
mal gastric en-
largements
(2) Needle
stick injury to
tubing
(3) Acute
cholecysti-
tis (+ cholecys-
tectomy)
(4) Hospital
admission for
depression
(5) Lost to fol-
low-up
(6) Un-
planned preg-
nancy
(1) 6
(2) 2
(3) 1
(4) 1
(5) 1
(6) 2
(1) 24
(2) 8
(3) 4
(4) 4
(5) 4
(6) 8
C: lifestyle
programme
25 2 8 (1) Hospi-
tal admission
for depression
and intracra-
nial hyperten-
sion
(2) Cholelithi-
asis (+ chole-
cystectomy)
(3) Lost to fol-
low-up
(4) Un-
(1) 1
(2) 1
(3) 7
(4) 2
(1) 4
(2) 4
(3) 28
(4) 8
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planned preg-
nancy
all: 50 11 22
“-” denotes not reported
C: comparator; I: intervention
Appendix 11. Survey of authors providing information on included trials
Study author contacted
[DD/MM/YY]
Study author replied
[DD/MM/YY]
Study author asked for
additional information
[short summary]
Study author provided
data
[short summary]
O’Brien 2010 24/01/2014
24/04/2014
24/01/2014
30/04/2014
Asked to provide data on
outpatient visits for ad-
verse events table and to
describe how allocation
was concealed
Author provided data
on number of outpa-
tient visits but stressed
that these were not ad-
verse events. He also
confirmed allocationwas
concealed
AC-
TRN12609001004257
31/03/2015 20/04/2015 Asked on the
current status of the trial
and whether results were
published
Currently 23 partici-
pants in the control arm
and 21 participants in
the intervention arm.
Recruitment will con-
tinue until 50 partici-
pants are included
Appendix 12. Health-related quality of life: instruments
Name
[type of
measure-
ment]
Dimen-
sions
(sub-
scales)
Validated
instru-
ment
Answer
options
Scores Minimum
score
Maximum
score
Weighting
of scores
Direction
of
scales
Minimal
important
difference
Child
Health
Question-
naire
(G)
BE - global
behaviour
BEHAV
BP - bodily
pain
Multidi-
mensional
generic
measure
of HrQoL;
Likert rat-
ing scale
Scores
can be
analysed
separately,
the CHQ
Scores are
trans-
formed
to a 0-100
scale, with
None Range on
sub-
scales and
the overall
scale is 0-
Poor
HRQoL
has been
defined as
2 SDs be-
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CH
- change in
health
FA - family
activities
FC
- family co-
hesion
GH - gen-
eral health
MH -
mental
health
PE
- parental
impact
emotional
PF - phys-
ical func-
tioning
PT
- parental
impact
time
REB - role
social-
emotional
behaviour
RP -
role social-
physical
SE - self-
esteem
validated profile
scores, or
combined
to derive
an overall
physical
and psy-
chosocial
score, the
CHQ
summary
scores;
the CHQ
measures
14 unique
physical
and psy-
chosocial
concepts
(physical
function-
ing, role/
social-
physical,
general
health per-
ceptions,
bodily
pain,
parental
time
impact,
parental
emotional
impact,
parental
emotional
impact,
role/social-
emo-
tional/be-
havioural,
self-es-
teem,
mental
health,
a mean of
50 and an
SD of 10
100, where
0 = worst
possible
health state
and 100 =
best possi-
ble health
state; indi-
vidual
or popula-
tion means
of can be
com-
pared to a
normative
sample
low the
mean of
the norma-
tive sample
or a phys-
ical func-
tioning or
psychoso-
cial health
summary
score <30
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general
behaviour,
family
activities,
family
cohesion,
change in
health);
the parent
form is
available in
2 lengths
- 50 or 28
items
O’Brien
2010
LAGB
(initial)
[SD/me-
dian and
interquar-
tile range]
N = 25
LAGB (fi-
nal)
[SD]
N = 24
Intra-
group P
value
Lifestyle
(initial)
[SD/me-
dian and
interquar-
tile range]
N = 25
Lifestyle
(final)
[SD]
N = 18
Intra-
group P
value
Inter-
group P
value
Commu-
nity
norms
BE 59.1 (19) 64.0 (21) 0.42 58.0 (19) 58.6 (19) 0.80 0.27 77.5
FA 70.5 (23) 85.6 (16) 0.006 73.1 (18) 80.2 (23) 0.60 0.12 72.5
FC 52.8 (24) 50.8 (32) 0.76 62.8 (23) 70.8 (23) 0.48 0.52 71.2
GH 47.8 (17) 65.7 (21) 0.003 47.1 (15) 53.7 (15) 0.044 0.37 68.1
MH 75.0 (65-
81)
73.0 (3.3) 0.66 65.6 (56-
75)
67.0 (2.5) 0.90 0.69 74.9
PF 73.1 (18) 94.4 (6.6) <.001 80.4 (20) 78.1 (24) 0.79 0.002 94.8
SE 55.9 (18) 70.3 (21) 0.012 60.5 (15) 62.7 (22) 0.94 0.21 74.6
CH 2.48 (0.8) 4.38 (0.8) <.001 2.96 (0.8) 3.56 (1.2) 0.094 0.006 3.54
CHQ: child health questionnaire; G: generic; HrQoL: health-related quality of life; LABG: laparoscopic adjustable gastric banding;
SD: standard deviation
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WH A T ’ S N E W
Last assessed as up-to-date: 30 March 2015.
Date Event Description
23 July 2014 Amended Given the rapid growth in the treatment of child and adolescent obesity, the original review formerly
published as “Interventions for treating obesity in children and adolescents” has now been split into six
separate reviews (see Differences between protocol and review).
C O N T R I B U T I O N S O F A U T H O R S
Louisa J Ells (LJE): search strategy development, acquiring trial reports, trial selection, data extraction, data analysis, data interpretation,
review draft and update draft.
EmmaMead (EM): search strategy development, acquiring trial reports, trial selection, data extraction, data analysis, data interpretation,
review draft and update draft.
Greg Atkinson (GA): search strategy development, trial selection, data extraction, data analysis, data interpretation, review draft and
update draft.
Louise Baur (LB): search strategy development, trial selection, data interpretation, review draft and update draft.
Eva Corpeleijn (EC): search strategy development, trial selection, data interpretation, review draft and update draft.
Russell Viner (RV): interpretation, review draft and update draft.
Kath Roberts (KR): trial selection, data extraction, data analysis, data interpretation, review draft and update draft.
Maria-Inti Metzendorf (MIM): search strategy development, update draft.
Bernd Richter (BR): acquiring trial reports, trial selection, data extraction, data analysis, data interpretation, review draft and update
draft.
D E C L A R A T I O N S O F I N T E R E S T
LJE: none known.
EM: none known.
GA: none known.
LB: none known.
EC: none known.
RV: none known.
KR: none known.
MIM: none known.
BR: none known.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Given the rapid growth in the treatment of child and adolescent obesity, the original review has now been split into six separate reviews,
with a specific intervention and age focus.
1. Diet, physical activity and behavioural interventions for the treatment of overweight or obesity in adolescents aged 12 to 17 years.
2. Diet, physical activity and behavioural interventions for the treatment of overweight or obesity in children aged 5 to 11 years.
3. Diet, physical activity and behavioural interventions for the treatment of overweight or obesity in infants aged 0 to 4 years.
4. Drug interventions for the treatment of obesity in children and adolescents.
5. Parent only interventions for childhood overweight or obesity.
6. Surgery for the treatment of obesity in children and adolescents.
A new search strategy was developed (see Appendix 1) to reflect advances in bariatric surgery that may not have been adequately captured
by the original search strategy.
N O T E S
Part of the background, the methods section, the appendices, additional tables, Figure 1 and Figure 2 of this review are based on a
standard template established by the CMED Group.
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